<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88387</article-id><article-id pub-id-type="doi">10.7554/eLife.88387</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88387.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waki</surname><given-names>Kentarou</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tani</surname><given-names>Hideki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6309-277X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>Eigo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Saga</surname><given-names>Yumiko</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Takahisa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yamazaki</surname><given-names>Emiko</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Koike</surname><given-names>Seiichi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8203-4498</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morinaga</surname><given-names>Yoshitomo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Isobe</surname><given-names>Masaharu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kurosawa</surname><given-names>Nobuyuki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1548-4541</contrib-id><email>kurosawa@eng.u-toyama.ac.jp</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0445phv87</institution-id><institution>Laboratory of Molecular and Cellular Biology, Graduate School of Science and Engineering for Education, University of Toyama</institution></institution-wrap><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a3bx267</institution-id><institution>Department of Virology, Toyama Institute of Health</institution></institution-wrap><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0445phv87</institution-id><institution>Department of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0445phv87</institution-id><institution>Center for Advanced Antibody Drug Development, University of Toyama</institution></institution-wrap><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0445phv87</institution-id><institution>Laboratory of Molecular and Cellular Biology, Graduate School of Innovative Life Science, University of Toyama</institution></institution-wrap><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard T.H. Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>05</month><year>2025</year></pub-date><volume>12</volume><elocation-id>RP88387</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-04-24"><day>24</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-04-11"><day>11</day><month>04</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.10.536311"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-07"><day>07</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88387.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-16"><day>16</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88387.2"/></event></pub-history><permissions><copyright-statement>Â© 2023, Waki et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Waki et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88387-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88387-figures-v1.pdf"/><abstract><p>Intranasal vaccination is an attractive strategy for preventing COVID-19 disease as it stimulates the production of multimeric secretory immunoglobulin A (IgA), the predominant antibody isotype in the mucosal immune system, at the target site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, intranasal vaccine efficacy is evaluated based on the measurement of polyclonal antibody titers in nasal lavage fluid. However, how individual multimeric secretory IgA protects the mucosa from SARS-CoV-2 infection remains to be elucidated. To understand the precise contribution and molecular nature of multimeric secretory IgA induced by intranasal vaccines, we developed 99 monoclonal IgA clones from nasal mucosa and 114 monoclonal IgA or IgG clones from nonmucosal tissues of mice that were intranasally immunized with the SARS-CoV-2 spike protein. The nonmucosal IgA clones exhibited shared origins and common and unique somatic mutations with the related nasal IgA clones, indicating that the antigen-specific plasma cells in the nonmucosal tissues originated from B cells stimulated at the nasal mucosa. Comparing the spike protein binding reactivity, angiotensin-converting enzyme-2-blocking, and in vitro SARS-CoV-2 virus neutralization of monomeric and multimeric secretory IgA pairs recognizing different epitopes showed that even non-neutralizing monomeric IgAs, which represent 70% of the nasal IgA repertoire, can protect against SARS-CoV-2 infection when expressed as multimeric secretory IgAs. We also demonstrated that the intranasal administration of multimeric secretory IgA delivered as prophylaxis in the hamster model reduced infection-induced weight loss. Our investigation is the first to demonstrate the function of nasal IgA at the monoclonal level, showing that nasal immunization can provide effective immunity against SARS-CoV-2 by inducing multimeric secretory IgAs at the target site of the virus infection.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>IgA</kwd><kwd>SARS-CoV-2</kwd><kwd>intranasal vaccination</kwd><kwd>monoclonal antibody</kwd><kwd>plasma cell</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>19187977</award-id><principal-award-recipient><name><surname>Isobe</surname><given-names>Masaharu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>22H02875</award-id><principal-award-recipient><name><surname>Kurosawa</surname><given-names>Nobuyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>20333128</award-id><principal-award-recipient><name><surname>Isobe</surname><given-names>Masaharu</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>22723616</award-id><principal-award-recipient><name><surname>Isobe</surname><given-names>Masaharu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analysis of monoclonal immunoglobulin A (IgA) antibodies after intranasal immunization highlights the crucial role of secretory IgA in mucosal immunity, enhancing our understanding of how intranasal vaccines can protect against SARS-CoV-2 infection.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Immunoglobulin A (IgA) is differentially distributed between the systemic and mucosal immune systems (<xref ref-type="bibr" rid="bib26">Li et al., 2020</xref>). Monomeric IgA (M-IgA) is predominantly present in serum, whereas secretory IgA (S-IgA) is the most prevalent in mucous secretions. S-IgA comprises two IgA units and one J-chain, which are synthesized and assembled in local plasma cells. Secretory components expressed on the basolateral surface of mucosal epithelial cells bind the IgA complex through the J-chain and transport the molecule to the apical cell membrane (<xref ref-type="bibr" rid="bib47">Woof and Kerr, 2006</xref>). Recent studies have shown that S-IgA in the nasal mucosa exists not only as dimers but also as trimers and tetramers in the human upper respiratory mucosa (<xref ref-type="bibr" rid="bib36">Saito et al., 2019</xref>). S-IgA plays an important role in the protection and homeostatic regulation of the airway, intestinal and vaginal epithelium through a process known as immune exclusion and immunosuppression (<xref ref-type="bibr" rid="bib29">Matsumoto, 2022</xref>). Recent studies have demonstrated that multimeric S-IgA is more effective and provides greater cross-protection than IgG and M-IgA (<xref ref-type="bibr" rid="bib33">Okuya et al., 2020b</xref>; <xref ref-type="bibr" rid="bib3">Asahi et al., 2002</xref>; <xref ref-type="bibr" rid="bib13">Dhakal et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Asahi-Ozaki et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Wang et al., 2021</xref>).</p><p>COVID-19 is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes mild upper respiratory symptoms in most cases, but some patients develop bilateral pneumonia with acute respiratory distress (<xref ref-type="bibr" rid="bib8">Budinger et al., 2021</xref>). The SARS-CoV-2 spike protein expressed on the virus surface is a multidomain homotrimer protein composed of an S1 domain consisting of an N-terminal domain (NTD) and receptor binding domain (RBD) and an S2 domain that mediates fusion of the virus and host cell membrane. Viral infection is initiated through the interaction between the RBD and the host receptor angiotensin-converting enzyme-2 (ACE2) (<xref ref-type="bibr" rid="bib20">Jackson et al., 2022</xref>). Thus, the spike protein is the main target for current vaccine development because antibodies against this protein can neutralize the infection. Currently approved intramuscular COVID-19 vaccines predominantly induce a systemic immune response by producing IgG in serum before they cause severe tissue damage, resulting in a high degree of efficacy (<xref ref-type="bibr" rid="bib35">Polack et al., 2020</xref>). However, these vaccines mainly induce IgG and M-IgA in serum; they do not induce S-IgA, which coats the upper respiratory tract mucosal surface (<xref ref-type="bibr" rid="bib12">DeFrancesco, 2020</xref>). The emergence of highly infectious SARS-CoV-2 omicron variants may undermine the therapeutic efficacy of vaccines, requiring more effective vaccination to prevent SARS-CoV-2 infection. Since nose epithelial cells are a primary target for SARS-CoV-2, intranasal vaccinations that induce S-IgA in the upper respiratory tract are desirable for protection against the infection and transmission of the virus (<xref ref-type="bibr" rid="bib41">Sungnak et al., 2020</xref>). To date, some intranasal vaccines are under development and have shown robust mucosal and humoral immune responses in animal models (<xref ref-type="bibr" rid="bib19">Houston, 2023</xref>; <xref ref-type="bibr" rid="bib10">Chavda et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Alu et al., 2022</xref>; <xref ref-type="bibr" rid="bib6">Barrett et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Bricker et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">DâArco et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib44">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Ohtsuka et al., 2021</xref>). However, there have been few published clinical trials of intranasal SARS-CoV-2 vaccines on humans (<xref ref-type="bibr" rid="bib15">Ewer et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Zhu et al., 2023</xref>). To evaluate the response to intranasal vaccines, researchers have utilized nasal lavage fluids containing polyclonal S-IgA (<xref ref-type="bibr" rid="bib27">Maltseva et al., 2022</xref>; <xref ref-type="bibr" rid="bib17">Gianchecchi et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Wong et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Afkhami et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Sui et al., 2021</xref>; <xref ref-type="bibr" rid="bib5">Azzi et al., 2022</xref>). However, obtaining information about the functions of individual antibodies in the polyclonal antiviral mucosal repertoire is challenging due to the broad nature of such assays. It has also been shown that intranasal vaccination induces a systemic antibody response, but the origin of these antibodies has not previously been investigated at the molecular level (<xref ref-type="bibr" rid="bib43">Tumpey et al., 2001</xref>; <xref ref-type="bibr" rid="bib50">Zhu et al., 2023</xref>). Thus, intranasal vaccines require novel approaches to evaluate the quality and quantity of IgA response.</p><p>To understand the precise contribution and molecular nature of S-IgA induced by intranasal vaccines in relation to its antiviral function, it is essential to develop monoclonal S-IgAs from plasma cells localized in the nasal mucosa and study their function. However, because of the difficulties in developing monoclonal IgA antibodies from nasal mucosal tissue, many studies have used artificial switching of IgG to IgA for recombinant production, and this approach has been used to study the protective properties of IgA against pathogens (<xref ref-type="bibr" rid="bib14">Ejemel et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Saito et al., 2019</xref>). Such technological limitations have hampered the biochemical and clinical evaluation of intranasal vaccination at the molecular level.</p><p>Our group has established robust protocols for isolating single antigen-specific plasma cells from a variety of animals and the high-throughput production of monoclonal antibodies (<xref ref-type="bibr" rid="bib24">Kurosawa et al., 2012</xref>). Here, using this technology, we developed 213 antigen-specific monoclonal antibodies from plasma cells derived from mice that were intranasally immunized with a stabilized SARS-CoV-2 spike trimer protein (Spike) and demonstrated that intranasal immunization induced potentially nasal-derived antibodies in the spleen, lung, and blood. Analysis of the properties of monoclonal IgAs recognizing different epitopes revealed that multimerization of M-IgAs could induce neutralizing activity in vitro and in vivo. These results are the first of their kind to be demonstrated by obtaining monoclonal S-IgAs from nasal mucosal tissue. Our data provide insights into the nasal immunity that may help shape future intranasal vaccine development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Development of anti-spike monoclonal M-IgAs from plasma cells localized in nasal mucosa</title><p>To evaluate the immune response after the intranasal administration of the SARS-CoV-2 spike protein of the Wuhan-Hu-1/D614G strain (Spike<sub>Wuhan</sub>), nasal lavage fluids and serum were collected from the mice 1 week after the last immunization. The intranasal administration of Spike<sub>Wuhan</sub> induced high levels of antigen-specific IgA but not IgG in nasal lavage fluids compared with those of the phosphate-buffered saline (PBS) control (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Isolation of antigen-specific IgA<sup>+</sup> plasma cells from mice that were intranasally immunized with Spike<sub>Wuhan</sub>.</title><p>(<bold>A</bold>) Mice were inoculated intranasally with 10 Î¼g of Spike<sub>Wuhan</sub> and 1 Î¼g of cholera toxin as an adjuvant in 10 Î¼l of phosphate-buffered saline (PBS), delivering the fluid dropwise into the nostril a total of three times at 3-week intervals. Nasal lavage fluid and serum were collected from the mice 1 week after the last immunization, and antibody responses were evaluated using enzyme-linked immunosorbent assay (ELISA) (n=5) (âââp&lt;0.001) . The antibody titers are expressed as optical density (OD<sub>450</sub>) value per total protein in nasal lavage fluids or serum. (<bold>B</bold>) Fluorescence-activated cell sorting (FACS) gating strategy for the isolation of S1-specific plasma cells from mice. Plots represent the sequential gating strategy. Lymphocytes (R1 gate) were stained with anti-CD138 and ER-Tracker to enrich plasma cells (CD138<sup>+</sup> ER-Tracker<sup>High</sup> fraction, R2 gate). IgA<sup>+</sup> plasma cells gated in R3 were selected from the R2-gated plasma cell fraction by staining with anti-IgA antibody. The antigen-specific plasma cells gated in R4 were further selected from the R3-gated Ig A<sup>+</sup> plasma cell fraction by staining with S1 domain of Wuhan severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (<bold>S1</bold>). The numbers indicate the percentages of cells in the gated area. A total of 100,000 events were recorded. Representative data from the No. 1 mouse are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Isolation of antigen-specific IgA<sup>+</sup> plasma cells from mice that were intranasally immunized with Spike<sub>Wuhan</sub>.</title><p>(<bold>A</bold>) The plots illustrate the sequential gating strategy used to identify SRS-S1-specific IgA-positive plasma cells in a control mouseâs nasal mucosa and spleen. (<bold>B</bold>) The plots depict the sequential gating strategy for isolating SRS-S1-specific IgA-positive plasma cells in the immunized mouseâs bone marrow and Peyerâs patches.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Elevated levels of antigen-specific IgA and IgG responses were detected in serum from the immunized mice, consistent with a prior study demonstrating that intranasal vaccinations induce both nasal and serum IgA levels (<xref ref-type="bibr" rid="bib39">Sterlin et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Maltseva et al., 2022</xref>). We selected three immunized mice with high nasal IgA titers and isolated antigen-specific plasma cells from the nasal mucosa, spleen, lung, and blood. Cells isolated from these tissues were stained with fluorescently labeled anti-CD138, ER-Tracker Blue-White DPX (ER-Tracker), anti-IgA, and S1 domain of Spike<sub>Wuhan</sub> (S1), and then antigen-specific plasma cells defined as anti-CD138<sup>+</sup>, ER-Tracker<sup>high</sup>, anti-IgA<sup>+</sup>, and S1<sup>+</sup> were isolated by fluorescence-activated cell sorting (FACS). ER-Tracker is a fluorescent dye that is highly selective for the endoplasmic reticulum of living cells. Because plasma cells have an expanded endoplasmic reticulum for properly folding and secreting large quantities of antibodies, using ER-Tracker along with anti-CD138 facilitates the isolation of plasma cells from lymphocytes without the need for additional antibodies (<xref ref-type="bibr" rid="bib24">Kurosawa et al., 2012</xref>). Consistent with the pattern of the IgA response observed in nasal lavage fluid, the proportions of antigen-specific IgA<sup>+</sup> plasma cells in the nasal mucosa of immunized mice were significantly higher than those of control mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>).</p><p>Cognate pairs of immunoglobulin heavy chain variable (VH) and kappa light chain variable (VL) genes were amplified by rapid amplification of 5' cDNA ends PCR from the single-sorted cells. After constructing full-length immunoglobulin heavy and kappa light chain genes, antibodies were expressed by DNA transfection into CHO-S cells. Antigen-specific antibody clones were identified by enzyme-linked immunosorbent assay (ELISA) with immobilized Spike<sub>Wuhan</sub>. After sequencing the entire coding region of heavy and light chain genes, the antibodies sharing the same V-(D)-J genes were grouped (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Then, representative antibody clones from each group were analyzed for their binding to the spike protein RBD of Wuhan, Beta, Kappa, and Delta variants and an NTD of Spike<sub>Wuhan</sub>. The antibodies were also analyzed for their ability to block ACE2 binding to RBDs and to neutralize the Wuhan pseudotyped virus. Based on their properties, each group of antibodies was arbitrarily categorized into five types. Type 1: anti-RBD, ACE2 blocking neutralizing antibody; Type 2: anti-RBD, <italic>ACE2 blocking</italic> non-neutralizing <italic>antibody</italic>; Type 3: anti-RBD, <italic>non-ACE2 blocking</italic> non-neutralizing <italic>antibody</italic>; Type 4: anti-NTD, non-ACE-2 blocking non-neutralizing <italic>antibody</italic>; and Type 5: <italic>non-ACE-2 blocking</italic> non-neutralizing antibody targeting epitopes other than RBD and NTD.</p></sec><sec id="s2-2"><title>Intranasal immunization induces functionally diverse IgA in the nasal mucosa and spleen</title><p>We conducted a detailed characterization of antibodies obtained from the No. 1 mouse, as many antigen-specific M-IgA clones were obtained. Of the 51 nasal M-IgA clones analyzed, they were classified into 11 groups based on their V-(D)-J usage, with the majority (83%) clonally expanding into four major clusters (G2, G3, G4, and G10) and the remainder (17%) scattered across branches (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Intranasal immunization induces functionally diverse antibodies in the nasal mucosa and spleen.</title><p>(<bold>A</bold>) Characterization of S1-specific monoclonal antibodies obtained from No. 1 mouse. The heatmap represents the relative intensity of antibody binding to receptor binding domains (RBDs) and blocking of the RBD-angiotensin-converting enzyme-2 (ACE2) interaction. Blue (0â25%), green (25â50%), orange (50â75%), and red (&gt;75%). N-terminal domain (NTD) binding was considered positive (+) when the OD at 405 nm was &gt;0.3 after the background was subtracted. Neutralizing activity was considered positive (+) when the antibody suppressed Wuhan pseudotyped virus infection by 50%. The figure reports values from a single experiment. UN, antibody type not determined. ND, antibody activity not determined. (<bold>B</bold>) Maximum-likelihood phylogenetic tree of the VH and VL chains of the S1-specific antibodies. Different colored fonts indicate antibodies obtained from the nose (red), spleen (blue), and lung (green). Bands on the outer ring indicate antibody groups. The color of the ring indicates antibody types: Type 1 (red), Type 2 (orange), Type 3 (green), Type 4 (blue), and Type 5 (gray). The antibody group is defined as clones using the same V-(D)-J usage and having an overall sequence identity of at least 95% from the signal peptide to framework 4 (FR4). The prefixes N, S, and L in the antibody clone numbers refer to antibodies derived from the nose, spleen, and lung, respectively. The suffixes A, G, and K in the antibody clone numbers refer to alpha, gamma, and kappa chains, respectively. (<bold>C</bold>) Nucleotide sequence alignment of VH and VL genes in the G2 and G3 antibodies from No. 1 mouse. The VH and VL sequences from the beginning of the signal peptide through the end of FR4 are shown as horizontal lines. Nucleotide changes relative to S632A and N109A are depicted as vertical bars across the horizontal lines. Different colored fonts indicate antibodies derived from the nose (red) and spleen (blue). Antibody phylogenetic trees based on VH/VK paired sequences are depicted. Gray circles represent the hypothetical germline configuration. White circles represent hypothetical ancestors. Colors indicate nasal (red) and splenic (blue) antibodies. Circles and squares indicate IgA and IgG, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Nucleotide sequence alignment of VH and VL genes in the G10 antibodies from No. 1 mouse.</title><p>The VH and VL sequences from the beginning of the signal peptide through the end of FR4 are shown as horizontal lines. Nucleotide changes relative to N220A are depicted as vertical bars across the horizontal lines. Different colored fonts indicate antibodies derived from the nose (red) and spleen (blue). Antibody phylogenetic trees based on VH/VK paired sequences are depicted. Gray circles represent the hypothetical germline configuration. White circles represent hypothetical ancestors. Colors indicate nasal (red), splenic (blue), and lung (green) antibodies. Circles and squares indicate IgA and IgG, respectively. The antibodies in the G1-G4 clusters were categorized as Type 1. The G1 antibody appeared only once. This clone displayed potent binding to the Wuhan, Kappa, and Delta RBD, and moderately to the Beta RBD. It also blocked ACE2 binding to all RBDs except the Beta RBD. The antibodies in G2-4 clusters bound to Wuhan and Delta RBD but not Beta and Kappa RBD. They were able to block ACE2 binding to the RBD of Wuhan and Delta but not to the RBD of Beta and Kappa. The antibodies in G5-G9 clusters were categorized as Type 2, bound to all four RBD variants, and uniformly blocked ACE2 binding to the RBDs of all four strains. G10 antibodies were classified as Type 3, accounting for 38% of the nasal IgA repertoire. They bound to the RBDs of all four strains but did not prevent ACE2 binding to the RBDs of any of the strains. The G11 antibody, classified as Type 4, was an anti-NTD antibody that did not prevent ACE2 binding to the RBDs of any strains.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Intranasal immunization induces potentially nasal-derived antibodies in the spleen, lung, and blood</title><p>Previous reports suggest that class-switched, affinity-matured B cells selected by NALT migrate to the regional lymph node and then return to the nasal mucosa and nonmucosal tissues to differentiate into plasma cells (<xref ref-type="bibr" rid="bib38">Shimoda et al., 2001</xref>). If this is the case, a fraction of S1-specific plasma cells differentiated from nose-originated B cells may reside in the spleen and produce antibodies. To directly evaluate the cellular origin of the anti-S1 antibodies in nonmucosal tissues, we analyzed the presence of S1-specific plasma cells in the spleen, lung, bone marrow, and Peyerâs patches. FACS analysis of splenocytes harvested from No. 1 mice showed the presence of S1-specific IgA<sup>+</sup> plasma cells, but the splenocytes harvested from control mice did not exhibit S1-specific IgA<sup>+</sup> plasma cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). Single-cell-based immunoglobulin gene cloning from the splenocytes of No. 1 mouse resulted in the successful production of 57 S1-specific monoclonal IgAs. DNA sequence analysis of these clones revealed significant clonal overlap between the nose and spleen (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Clonal overlap was found in the G2-G3, G5, G6, and G10 clusters, in which G10 possessed the most expanded splenic clones, as in the case of nasal IgA. Further investigation was conducted to determine if plasma cells expressing S1-specific IgG<sup>+</sup> antibody, which share V-(D)-J with nasal IgA, could be identified in the spleen. Although the number of antigen-specific IgG<sup>+</sup> plasma cells was limited, eight IgG clones specific for S1 were isolated, among which five were potentially nasal-derived. When we attempted to isolate antigen-specific IgA<sup>+</sup> plasma cells from the lung, nine S1-specific IgA clones were obtained, among which three were potentially nasal-derived. The gut mucosa and bone marrow possessed a large population of IgA<sup>+</sup> plasma cells. However, we could not detect S1-specific IgA<sup>+</sup> plasma cells in Peyerâs patches and bone marrow (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>Next, we focused on the expanded antibody groups G2, G3, and G10 to analyze the patterns of somatic hypermutation (SHM). We found complex patterns of shared and unique SHMs in antibodies obtained from the nose, spleen, and lung. In G2, the VHs of the three splenic clones (S530A, S208G, and S619A) had the same sequence, except for framework 4 of an IgG clone (S208G) and had three shared SHMs with the nasal clones (N219A and N226A). In addition, the VKs of the three splenic clones and N226A had the same sequence. In Group 3, seven nasal clones (N109A, N112A, N135A, N139A, N244A, N245A, and N715A) and two splenic clones (S545 and S607) were 100% identical in the nucleotide sequence, with N135A and N245 differing from the other clones by only one nucleotide in their VKs (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Sequence analysis of the most expanded group, Group 10, also demonstrated clonal overlap in the nose, lung, and spleen. For example, the VHs of a nasal clone (N221), spleen clones (S647, S503, S640, and S543), and a lung clone (L009) were 100% identical, with S647 differing from the other clones by only one nucleotide in VK (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). Antibody lineage analysis of these clones suggests that each family of related antibodies originates from a common ancestor gene that was subjected to class switching and SHM. We also developed S1-specific antibodies from No. 2 and No. 3 mice and analyzed their sequences (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>In No. 2 mice, we obtained 29 nasal IgAs, 15 splenic antibodies (13 IgAs and 2 IgGs), 5 lung IgAs, and 6 blood IgAs. They were classified into 17 groups based on their V-(D)-J usage, and each group was categorized as either Type 1, 2, 3, 4, or 5 based on antibody properties (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Potentially nasal-derived clones were found in the spleen, lung, and blood (G5, -6, and -8). These clones also showed a complex pattern of shared and unique SHM with nasal clones throughout the full length of the VH and VL genes. In mouse No. 3, we cloned 19 nasal IgAs and 22 splenic antibodies (17 IgAs and 5 IgGs). They were classified into 10 groups, and each group was categorized as either Type 1, 3, 4, or 5. A high degree of clonal overlap between the nose and spleen was found, in which 13 out of 22 splenic antibodies were potentially nasal-derived clones (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). Analysis of the VH and VL repertoires of the three mice revealed that the expanded clones constituted varying fractions of the antibody repertoire among different mice despite having received the same antigen, and no group of antibodies stood out across mice, suggesting that individual mice had immunologically distinct responses (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>). In all mice, only a few bound to the NTD, and most of them were RBD-directed. Approximately 30% of M-IgAs categorized as Type 1 showed neutralizing activity. Taken together, regarding the mutation frequency and the pattern of SHM, it can be assumed that B cells stimulated by nasal challenges were the major precursor of antigen-specific plasma cells in the spleen, lung, and blood, which may contribute to antibody production in the lower respiratory tract and systemic circulation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Characterization of S1-specific monoclonal antibodies obtained from No. 2 mouse.</title><p>(<bold>A</bold>) A total of 51 S1-reactive antibodies were analyzed for their properties as in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. UN, antibody type not determined. ND, antibody activity not determined. (<bold>B</bold>) Maximum-likelihood phylogenetic tree of the VH and VL chains of the S1-specific antibodies. Different colored fonts indicate antibodies obtained from the nose (red), spleen (blue), lung (green), and blood (magenta). Bands on the outer ring indicate antibody groups. The color of the band indicates antibody types: Type 1 (red), Type 2 (orange), Type 3 (green), Type 4 (blue), and Type 5 (gray). The prefixes N, S, and L in the antibody clone numbers refer to antibodies derived from the nose, spleen, and lung, respectively. The suffixes A, G, and K in the antibody clone numbers refer to alpha, gamma, and kappa chains, respectively. (<bold>C</bold>) Nucleotide sequence alignment of VH and VL genes in the G6 and G8 antibodies from No. 2 mouse. The nucleotide changes relative to N5120A and N5105A are depicted as vertical bars across the horizontal lines. Different colored fonts indicate antibodies derived from the nose (red), spleen (blue), lung (green), and blood (magenta). Antibody phylogenetic trees based on VH/VK paired sequences are depicted. Gray circles represent the hypothetical germline configuration. White circles represent hypothetical ancestors. Colors indicate nasal (red), splenic (blue), lung (green), and blood (magenta) antibodies.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Characterization of S1-specific monoclonal antibodies obtained from No. 3 mouse.</title><p>(<bold>A</bold>) A total of 41 S1-reactive antibodies were analyzed for their properties. UN, antibody type not determined. ND, antibody activity not determined. (<bold>B</bold>) Maximum-likelihood phylogenetic tree of the VH and VL chains of the S1-specific antibodies. Different colored fonts indicate antibodies obtained from the nose (red) and spleen (blue). Bands on the outer ring indicate antibody groups. The color of the band indicates antibody types: Type 1 (red), Type 2 (orange), Type 3 (green), Type 4 (blue), and Type 5 (gray). The prefixes N and S in the antibody clone numbers refer to antibodies derived from the nose and spleen, respectively. The suffixes A, G, and K in the antibody clone numbers refer to alpha, gamma, and kappa chains, respectively. (<bold>C</bold>) Nucleotide sequence alignment of VH and VL genes in the G1 and G3 antibodies from No. 3 mouse. The nucleotide changes relative to N26A and N29A are depicted as vertical bars across the horizontal lines. Different colored fonts indicate antibodies derived from the nose (red) and spleen (blue). Antibody phylogenetic trees based on VH/VK paired sequences are depicted. Gray circles represent the hypothetical germline configuration. White circles represent hypothetical ancestors. Colors indicate nasal (red) and splenic (blue) antibodies.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 2.</label><caption><title>Analysis of the VH and VL repertoires of the three mice.</title><p>(<bold>A</bold>) V genes are plotted numerically, with heights indicating the expression rate between VH or VL clusters. (<bold>B</bold>) Pie charts show the distribution of mAb obtained from three immunized mice. The number inside each circle denotes the number of mAb of each type. The pie size is proportional to the number of antibody clones. Pie charts show the distribution of mAb obtained from three immunized mice. The number inside each circle denotes the number of mAb of each type. The pie size is proportional to the number of antibody clones obtained from each mouse.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Multimerization of M-IgA enhances antigen-binding activity</title><p>To examine how IgA multimerization affects antigen-binding activity, four representative clones (N5203, N142, N114, and N217) were selected from each type of antibody, and S-IgAs were expressed by cotransfecting alpha heavy chain, kappa light chain, J-chain, and secretory component into CHO-S cells. Analysis of the purified S-IgAs by polyacrylamide gel electrophoresis (SDS-PAGE) revealed a band corresponding to the alpha heavy chain, kappa light chain, and secretory component. Native-PAGE analysis revealed that the antibodies comprised three quaternary structures, including a dimer (~400 kDa), a trimer (~550 kDa), and a tetramer (~750 kDa) at a molar ratio of 5:1:3 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Comparison of reactivity between monomeric and multimeric immunoglobulin As (IgAs).</title><p>(<bold>A</bold>) Production of recombinant monomeric IgAs (M-IgAs) and secretory IgAs (S-IgAs). Recombinant M-IgA and S-IgA purified from the culture supernatant of CHO cells were subjected to SDS-PAGE and Blue native-PAGE analysis. Bands corresponding to a monomer (M), dimer (Di), trimer (Ti), and tetramer (Te) are shown. H, Î± heavy chain; L, light chain; J, J-chain; SC, secretory component; M, M-IgA; S, S-IgA. (<bold>B</bold>) Binding dynamics of M-IgAs and S-IgAs to Wuhan, Delta, or Omicron spike protein by surface plasmon resonance (SPR). The S-IgAs used are a mixture of dimers, trimers, and tetramers. The observed values reflect the average affinity of the S-IgAs. The curves shown are representative of two or three determinations. RU, resonance units. Representative data from two independent experiments are shown. (<bold>C</bold>) The table shows the association (ka) (M<sup>â1</sup>s<sup>â1</sup>), dissociation (kd) (s<sup>â1</sup>) rate constants and apparent equilibrium dissociation constants (K<sub>D</sub>) expressed as the mean of two or three determinations (lower panel).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Raw uncropped native and SDS-PAGE data showing the Recombinant M-IgAs and S-IgAs.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88387-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4âsource data 2.</label><caption><title>Recombinant M-IgA and S-IgA raw native and SDS-PAGE data were labeled with their associated bands prior to sectioning.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88387-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig4-v1.tif"/></fig><p>Then, we compared the binding kinetics of each pair of M-IgA/S-IgA by surface plasmon resonance (SPR) with immobilized Spike<sub>Wuhan</sub>, Spike<sub>Delta</sub>, or Spike<sub>Omicron</sub>. As shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, N5203 M-IgA, which has a moderate binding affinity to Spike<sub>Wuhan</sub> (apparent equilibrium constant, K<sub>D</sub> = 5.2E-9), acquired dramatic enhancement of the binding activity to Spike<sub>Wuhan</sub> after multimerization (K<sub>D</sub> = 1.3E-13). However, multimerization did not enhance the binding activity to Spike<sub>Delta</sub> (K<sub>D</sub> = 2.1E-9). N142 M-IgA, which has a high affinity for Spike<sub>Wuhan</sub> (K<sub>D</sub> = 4.5E-11) and Spike<sub>Delta</sub> (K<sub>D</sub> = 7.8E-11), did not show enhanced binding activity to them after multimerization. Almost the same phenomenon was found for N114 M-IgA, which has a high affinity for Spike<sub>Wuhan</sub> (K<sub>D</sub> = 6.8E-11) and Spike<sub>Delta</sub> (K<sub>D</sub> = 9.7E-11). N142 M-IgA, which has the lowest affinity to Spike<sub>Wuhan</sub> (K<sub>D</sub> = 2.1E-8), also acquired dramatic enhancement of the binding activity to Spike<sub>Wuhan</sub> after multimerization (K<sub>D</sub> = 6.4E-11) but not to Spike<sub>Delta</sub>. All antibodies showed little or marginal levels of binding to Spike<sub>Omicron</sub>. These results suggest that the degree of avidity of S-IgAs depends on the affinity of the parent monomeric antibody: antibodies with low or intermediate affinity in the monomeric state (N5203 and N217) can increase their avidity by multimerization but not antibodies with high affinity in the monomeric state (N142 and N114). These results are consistent with recent work by Saito et al., who examined the function of multimerized IgA against influenza viruses (<xref ref-type="bibr" rid="bib36">Saito et al., 2019</xref>).</p></sec><sec id="s2-5"><title>Multimerization facilitates stronger neutralization activity in non-neutralizing M-IgA</title><p>Since ACE2-blocking activity is one indicator for evaluating the neutralizing activity of anti-SARS-CoV-2 antibodies, we next examined whether the multimerization of IgAs influences the RBD-ACE2 interaction by competitive ELISA (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Multimerization facilitates the neutralization activity of non-neutralizing monomeric immunoglobulin As (M-IgAs).</title><p>(<bold>A</bold>) Graphs of the competitive enzyme-linked immunosorbent assay (ELISA) results showing the binding of biotinylated angiotensin-converting enzyme-2 (ACE2) to the immobilized Wuhan, Delta, or Omicron receptor binding domain (RBD) in the presence of antibodies. The results are expressed as the mean Â± SD of three technical replicates. The figure reports values from a single experiment. The IC<sub>50</sub> values of the indicated antibodies that inhibit the RBD-ACE2 interaction are shown in the diagrams. (<bold>B</bold>) Comparison of neutralization activity between M-IgA and secretory IgA (S-IgA) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudotyped viruses. Neutralization curves of the indicated antibody against pseudotyped viruses bearing spike proteins of Wuhan, Delta, or Omicron are shown. Pseudotyped viruses preincubated with antibodies at the indicated concentrations were used to infect VeroE6 cells, and luciferase activities in cell lysates were measured at 20 hr post-transduction to calculate infection (%) relative to nonantibody-treated controls. The results are expressed as the mean Â± SD of three technical replicates. The NT<sub>50</sub> values of the indicated antibodies are shown in the diagrams. Antibodies that did not reach &gt;70% inhibition at the highest concentration tested were listed as data not determined (ND). (<bold>C</bold>) Comparison of neutralization potential between M-IgA and S-IgA against authentic SARS-CoV-2 BA.1. The neutralizing potential of the antibody was determined using a reverse transcription polymerase chain reaction (RT-PCR)-based SARS-CoV-2 neutralization assay. VeroE6 cells preincubated with authentic SARS-CoV-2 BA.1 virus were incubated with the indicated antibodies at various concentrations. The virus in the cell culture medium was measured at 48 hr post-transduction to calculate infection (%) relative to non-antibody-treated controls. The results are expressed as the mean Â± SD of three technical replicates. The NT<sub>50</sub> values of the indicated antibodies are shown in the diagrams. Antibodies that did not reach &gt;50% inhibition at the highest concentration tested are listed as ND. **p&lt;0.01.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig5-v1.tif"/></fig><p>Although the multimerization of N5203 M-IgA led to the dramatic enhancement of Spike<sub>Wuhan</sub> binding, it only increased RBD<sub>Wuhan</sub>-ACE2 blocking by 3.3-fold, and there were no differences in RBD<sub>Delta</sub>-ACE2 blocking between M-IgA and S-IgA. In N142 M-IgA, multimerization slightly increased RBD<sub>Wuhan</sub>-ACE2 blocking but not RBD<sub>Delta</sub>-ACE2 blocking. Multimerization of N114 and N217 M-IgA did not enhance RBD<sub>Wuhan</sub>-ACE2 and RBD<sub>Delta</sub>-ACE2 blocking, as in the case of their monomeric forms. None of the antibodies showed RBD<sub>Omicron</sub>-ACE2 blocking even at the highest antibody concentrations.</p><p>To analyze whether multimerization affects the functionality of M-IgAs, we tested all M-IgA/S-IgA pairs for their ability to neutralize pseudotyped lentiviruses bearing the Wuhan, Delta, or Omicron spike protein (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Both monomeric and multimeric forms of N5203 showed strong neutralizing activity against the Wuhan and Delta pseudotyped lentiviruses, but the concentrations required to achieve the 50% neutralizing titer (NT<sub>50</sub>) were almost the same for both. Although both forms of N142 displayed RBD<sub>Wuhan</sub>-ACE2 and RBD<sub>Delta</sub>-ACE2 blocking, only the multimeric form showed neutralization activity against the Wuhan and Delta pseudotyped lentiviruses. Notably, N114 M-IgA and N217 M-IgA, which did not have RBD<sub>Wuhan</sub>-ACE2 blocking activity, displayed neutralizing activity against the Wuhan but not the Delta pseudotyped lentivirus after multimerization. None of the antibodies exhibited neutralization activity against the Omicron pseudotyped lentivirus. We further tested the neutralization activity of these antibodies by using an authentic SARS-CoV-2 Wuhan strain (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). N5203 S-IgA showed twofold higher neutralization activity than its monomeric counterpart. As predicted from the results of the pseudotyped lentivirus assay, multimerization of N142, N114, and N217 M-IgA induced neutralization activity, while their monomeric counterparts failed to neutralize live virus at the highest antibody concentration. These results suggest that the neutralizing activity of S-IgAs is not solely attributed to the spike protein affinity and the RBD-ACE2 blocking activity of M-IgAs, and that the valence and binding mode between the epitope and paratope affect their function.</p><p>Next, we selected three types of S-IgAs (N5203, N142, and N217) and investigated whether nasally administered S-IgAs could protect against Wuhan SARS-CoV-2 infection in a Syrian hamster model as a prophylactic treatment (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The animals in the control group showed significant and progressive weight loss (20% by day 3) after the viral challenge. In contrast, animals treated with S-IgAs showed only a small weight loss (5% with N5203, 8% with N142, and 5% with N217) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Analysis of viral load at day 3 by qPCR for SARS-CoV-2 nucleoprotein (N2) RNA showed that some hamsters treated with N5203 S-IgA or N217 S-IgA showed a trend of decreased virus production in the nasal turbinate compared to the control. However, this did not reach statistical significance. These antibodies did not reduce the viral load in the lungs. These results indicate that the prophylactic nasal administration of S-IgA confers a protective effect against SARS-CoV-2, but does not lead to the elimination of the virus from the animals.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Intranasal administration of secretory immunoglobulin A (S-IgA) suppresses severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Syrian hamsters.</title><p>(<bold>A</bold>) Experimental schedule. Three groups of hamsters received a single intranasal dose of 1.0 mg/kg of S-IgA 3 hr before infection (â3) for pre-exposure prophylaxis and at 24 hr (24) and 48 hr post-infection for early treatment, respectively. Control hamsters (n=3) received phosphate-buffered saline (PBS) at the same dose. The figure reports values from a single experiment. On day 0, each hamster was intranasally challenged with the Wuhan SARS-CoV-2 virus (6Ã10<sup>5</sup> median tissue culture infectious dose). (<bold>B</bold>) Hamster body weights were recorded hourly (0, 24, 48, and 72 hr), and weight loss was defined as the percentage loss from 0 hr. Data represent the mean value Â± SD at the indicated time points (nâ=â3) at the indicated time points and were analyzed using a Kruskal-Wallis one-way ANOVA (âp&lt;0.05 and ââp&lt;0.01) . (<bold>C</bold>) Animals were euthanized 72 hr post-infection, and RNA was extracted from the nasal turbinates and lungs. The SARS-CoV-2 viral load was analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) targeting the SARS-CoV-2 nucleoprotein. Assays were normalized relative to total RNA levels. Data represent the mean value (nâ=â3) analyzed in one experiment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we generated hundreds of monoclonal antibodies from nasal mucosa and nonmucosal tissues, providing molecular evidence that intranasal immunization can induce both mucosal and systemic antibody responses. We also generated M-IgA and S-IgA with the same antigen recognition site for the Spike protein and compared their antiviral activities in vitro. SARS-CoV-2 research has mainly focused on anti-RBD neutralizing antibodies, while the role of non-neutralizing antibodies has not been adequately analyzed. We demonstrated that non-neutralizing M-IgAs, comprising 70% of the nasal IgA repertoire, showed strong neutralizing activity when expressed as S-IgAs. Nasal delivery of S-IgA offered potential prophylaxis against SARS-CoV-2 infection. The ability of nasal immunization to induce various neutralizing S-IgAs that recognize different epitopes may be a significant advantage not seen with injectable vaccines. Our data highlight the key role of S-IgA in the protective effect of mucosal immunity, which may be useful for better understanding how intranasal vaccines can help protect against SARS-CoV-2 infection.</p><p>It has been shown that the mucosal route of immunization elicits immune responses at local sites and systemic immune responses (<xref ref-type="bibr" rid="bib25">Lapuente et al., 2021</xref>). Our analysis demonstrated that the spleen possessed a larger population of antigen-specific plasma cells that expressed potentially nasal-derived IgAs and IgGs. These results suggest that the B cells activated in the nasal immune system give rise to plasma cells that reside in the nasal mucosa and produce S-IgA, while the B cells also migrate to the spleen and produce M-IgA and IgG. The role of the spleen in the induction of potentially nasal-derived antibodies by intranasal immunization is yet to be determined. The antigen-specific plasma cells in the spleen may respond in cases of systemic infection by supplying M-IgAs and IgGs into the bloodstream or protecting the body against subsequent infection (<xref ref-type="bibr" rid="bib1">Afkhami et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Sheikh-Mohamed et al., 2022</xref>). Although bone marrow and the intestines are reservoirs for IgA-producing B cells, we could not detect antigen-specific plasma cells in these tissues. The molecular mechanisms regulating potentially nasal-derived B-cell migration into the spleen but not into bone marrow and Peyerâs patches remain to be determined. The extent of functional and reactive differences between M-IgA and IgG sharing the same V gene remains to be determined in this paper. Recent studies on replacing the Fc domain of IgG with IgA have shown conflicting data, with some antibodies being enhanced, while others were weakened. This suggests that the degree of increase in antibody reactivity and functionality is not solely correlated with the Fc domain but also depends on the selected epitopes and paratopes (<xref ref-type="bibr" rid="bib42">Tudor et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Muramatsu et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Ejemel et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Saito et al., 2019</xref>).</p><p>As illustrated in <xref ref-type="fig" rid="fig7">Figure 7</xref>, four types of antibodies exhibited different reactions between M-IgA and S-IgA regarding spike protein binding, ACE2-blocking, and virus neutralization.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The affinity, angiotensin-converting enzyme-2 (ACE2) inhibitory activity, and the in vitro neutralizing activity of the indicated antibodies are illustrated in a 3D scatter plot.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88387-fig7-v1.tif"/></fig><p>N5203 M-IgA, categorized as Type 1, binds to the RBD<sub>Wuhan</sub> and RBD<sub>Delta</sub>, inhibits ACE2-binding to these RBDs, and effectively neutralizes Wuhan and Delta pseudotyped viruses. The multimeric form of this antibody had a minimal effect on ACE-blocking and neutralization breadth despite the increased affinity for Spike<sub>Wuhan</sub>. This suggests that the increase in valency does not necessarily correlate with an increase in functionality. N142 M-IgA, categorized as Type 2, binds to the RBD<sub>Wuhan</sub> and RBD<sub>Delta</sub>, inhibiting ACE2-binding to these RBDs, yet fails to neutralize the viruses. Interestingly, its S-IgA exhibited neutralization activity against both pseudotyped viruses without enhancing spike binding or ACE-blocking activity. These results suggest that the neutralizing activity of N142 S-IgA partially depends on the ACE2-blocking activity of the corresponding M-IgA, but its mechanism differs from that of N5203 S-IgA, whose monomeric form shows cross-neutralizing activity. Notably, two types of non-ACE2-blocking, non-neutralizing M-Abs (N114 and N217), expressed as S-IgA, gained the ability to neutralize the Wuhan but not the Delta pseudotyped viruses. These findings indicate that the two S-IgAs exert their neutralizing activity through mechanisms apart from the general ACE2-RBD axis.</p><p>Recent reports show that antibodies that induce inter- or intraspike cross-linking can inhibit viral binding or shedding by the host cell through steric hindrance or cause conformational changes in the spike proteins (<xref ref-type="bibr" rid="bib16">Galimidi et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Jackson et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Klein and Bjorkman, 2010</xref>). Such inter- and intraspike cross-linking may be limited in M-IgAs and IgGs if the spike protein density on the virus surface is low or if the epitopes are unfavorably located. We hypothesize that S-IgA could exert the above effects through its multivalent arms, a mode of action that is hard to achieve with M-IgA, and factors such as valency, epitope selection, antibody binding angle, and the bulkiness of the Fc are involved in this process (<xref ref-type="bibr" rid="bib32">Okuya et al., 2020a</xref>; <xref ref-type="bibr" rid="bib9">Callegari et al., 2022</xref>).</p><p>Intranasal delivery of monoclonal antibodies was shown to confer viral protection in a prophylactic setting in animal models (<xref ref-type="bibr" rid="bib18">Haga et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Zhou et al., 2023</xref>; <xref ref-type="bibr" rid="bib28">Marcotte et al., 2024</xref>). We have shown that hamsters receiving S-IgA intranasally are protected against weight loss by SARS-CoV-2 infection. However, this treatment did not decrease viral load in the nasal turbinates and lungs. Since the S-IgAs used in this experiment represent the general antibodies found in the nasal mucosa rather than the potent antibodies selected through screening, they lacked sufficient capacity to prevent viral infections completely. However, when these antibodies exist as polyclonal antibodies on the nasal mucosa, they may be more effective in preventing infections.</p><p>Our study has limitations, including that the number of antigen-specific plasma cells isolated from the nasal mucosa of immunized mice was insufficient for a comprehensive analysis of systemic and mucosal immune responses. In this study, antibodies that did not share V-(D)-J with nasal clones were found in the spleen, lungs, and blood of immunized mice. This finding was probably due to the limited number of clones that were isolated from the nose. However, we cannot exclude the possibility that these clones differentiated from local naÃ¯ve B cells. While S-IgA has many possible advantages in antibody therapy, S-IgA has the property of aggregating. Therefore, it encounters challenges in expression and stabilization. Addressing these issues is crucial for large-scale production for in vivo experiments.</p><sec id="s3-1"><title>Study approval</title><p>All experiments were performed in accordance with relevant guidelines and regulations. The Committee on Animal Experimentation at the University of Toyama approved the animal experimental protocols, which were conducted using project license A2017eng-1. All experiments involving live SARS-CoV-2 followed the approved standard operating procedures in the Biosafety Level 3 facility at the University of Toyama and Toyama Institute of Health.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Materials</title><p>The materials used in this study can be found in the Key resources table. VeroE6/TMPRSS2 cells were purchased from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (the National Institute of Biomedical Innovation, Health, and Nutrition, Osaka, Japan) (JCRB1819). CHO-S cells were purchased from Thermo Fisher Scientific (A29127). All cell lines tested negative for mycoplasma contamination, and the suppliers verified their authenticity through STR profiling. Female ICR mice (SLC:ICR) and female Syrian golden hamsters (SLC:Syrian) were purchased from Japan SLC, Inc (Tokyo, Japan).</p><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">IgHa</td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">AK136471</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">IGHA2</td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">AL389978</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">JCHAIN</td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">NM_144646</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">PIGR</td><td align="left" valign="bottom">NCBI</td><td align="left" valign="bottom">NM_002644.4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">ICR</td><td align="left" valign="bottom">SLC</td><td align="left" valign="bottom">SLC:ICR</td><td align="left" valign="bottom">Six-week-old female</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Syrian hamster</td><td align="left" valign="bottom">SLC</td><td align="left" valign="bottom">SLC:Syrian</td><td align="left" valign="bottom">Six-week-old female</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">VeroE6/TMPRSS2</td><td align="left" valign="bottom">JCRB, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_YQ49">CVCL_YQ49</ext-link></td><td align="left" valign="bottom">JCRB1819</td><td align="left" valign="bottom">Infection</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Cricetulus griseus</italic>)</td><td align="left" valign="bottom">CHO-S</td><td align="left" valign="bottom">Thermo Fisher, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_5J31">CVCL_5J31</ext-link></td><td align="left" valign="bottom">A29127</td><td align="left" valign="bottom">Antibody expression</td></tr><tr><td align="left" valign="bottom">Biological sample (virus)</td><td align="left" valign="bottom">SARS-CoV-2 virus</td><td align="left" valign="bottom">NIID</td><td align="left" valign="bottom">2019-nCoV/Japan/TY/WK-521/2020</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DyLight488-labeled goat anti-mouse IgA alpha chain</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab97011</td><td align="left" valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD138</td><td align="left" valign="bottom">BioLegend, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10915989">AB_10915989</ext-link></td><td align="left" valign="bottom">142503</td><td align="left" valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DyLight488-labeled goat anti-mouse IgG H&amp;L</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab96871</td><td align="left" valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Biotinylated SARS-CoV-2 S1 protein NTD, His, Avitag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">S1D-C52E2</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 (COVID-19) S protein RBD, His Tag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPD-C52H3</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 S protein RBD (K417N, E484K, N501Y), His Tag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPD-C52Hp</td><td align="left" valign="bottom">B.1.351/Beta Variant</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 Spike RBD (L452R, E484Q), His Tag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPD-C52Hv</td><td align="left" valign="bottom">B.1.617.1 (Kappa)</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 (COVID-19) S protein RBD (L452R, T478K), His Tag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPD-C52Hh</td><td align="left" valign="bottom">B.1.617.2/Delta</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Biotinylated Human ACE2</td><td align="left" valign="bottom">Sino Biological</td><td align="left" valign="bottom">10108-H08H-B</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">SARS-CoV-2 S protein, His Tag, Super stable trimer</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPN-C52H9</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Biotinylated SARS-CoV-2 S protein (D614G), His, Avitag, Super stable trimer</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPN-C82E3</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Biotinylated SARS-CoV-2 Spike Trimer, His, Avitag (B.1.1.529/Omicron)</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">SPNC82EE</td><td align="left" valign="bottom">B.1.1.529/Omicron</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Biotinylated SARS-CoV-2 (COVID-19) S1 protein (D614G), His, Avitag</td><td align="left" valign="bottom">Acro Biosystems</td><td align="left" valign="bottom">S1N-C82E3</td><td align="left" valign="bottom">Wuhan</td></tr><tr><td align="left" valign="bottom">Recombinant protein</td><td align="left" valign="bottom">Streptavidin Protein, DyLight 650</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">84547</td><td align="left" valign="bottom">Plasma cell isolation</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pET-mIgA</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Antibody expression plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pET-mIgK</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Antibody expression plasmid</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">THUNDERBIRD Probe One-step qRT-PCR Kit</td><td align="left" valign="bottom">TOYOBO</td><td align="left" valign="bottom">QRZ-101</td><td align="left" valign="bottom">qPCR</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SureBlue/TMB peroxidase substrate</td><td align="left" valign="bottom">Sera care</td><td align="left" valign="bottom">5120-0059</td><td align="left" valign="bottom">ELISA</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">N2 primer/probe set</td><td align="left" valign="bottom">Nihon Gene Research Laboratories</td><td align="left" valign="bottom">283-34201</td><td align="left" valign="bottom">qPCR</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CHOgro High Yield Expression System</td><td align="left" valign="bottom">TakaraBaio/Mirus BIo</td><td align="left" valign="bottom">MIR 6260</td><td align="left" valign="bottom">Antibody expression</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dynabeads mRNA Purification kit</td><td align="left" valign="bottom">Veritas</td><td align="left" valign="bottom">DB61006</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NativePAGE Bis-Tris Gel System</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">BN1001BOX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ER-Tracker BlueWhite DPX</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">E12353</td><td align="left" valign="bottom">Plasma cell isolation</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cholera toxin</td><td align="left" valign="bottom">Fujifilm</td><td align="left" valign="bottom">030-20621</td><td align="left" valign="bottom">Adjuvant</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GENETYX</td><td align="left" valign="bottom">NIHON SERVER</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Antibody sequence analysis</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Sequencher</td><td align="left" valign="bottom">Gene Codes</td><td align="left" valign="bottom">Version 5.4.6</td><td align="left" valign="bottom">Antibody sequence analysis</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RStudio</td><td align="left" valign="bottom">posit</td><td align="left" valign="bottom">Version 2022.12.0+353</td><td align="left" valign="bottom">Antibody lineage analysis</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Alakazam</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.rdocumentation.org/packages/alakazam/">https://www.rdocumentation.org/packages/alakazam/</ext-link></td><td align="left" valign="bottom">Versions/1.2.1</td><td align="left" valign="bottom">Antibody lineage analysis</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Peptide M Agarose</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">gel-pdm-2</td><td align="left" valign="bottom">IgA purification</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">TiterMax adjuvants</td><td align="left" valign="bottom">Merck Sigma-Aldrich</td><td align="left" valign="bottom">12352203</td><td align="left" valign="bottom">Immunization</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">âGoat Anti-Mouse IgA alpha chain (HRP)</td><td align="left" valign="bottom">abcam</td><td align="left" valign="bottom">ab97235</td><td align="left" valign="bottom">ELISA</td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Immunization</title><p>Anesthetized 6-week-old female ICR mice were intranasally immunized with 10 Î¼g of Spike<sub>Wuhan</sub> or PBS with 1 Î¼g of cholera toxin in 10 Î¼l of PBS by using a pipette to deliver the fluid dropwise into each nostril a total of three times at 3-week intervals. One week after the final immunization, <italic>mi</italic>ce were sacrificed by CO<sub>2</sub> inhalation, and blood samples were collected from the inferior vena cava. To avoid contamination with circulating blood lymphocytes, the mice were perfused with 2 ml of PBS via the heart. Then, the lungs, the spleen, bone marrow, and Peyerâs patches were dissected, and single-cell suspensions were obtained by mincing the tissue using a 100 Î¼m nylon mesh. The mice were decapitated at the larynx. After the removal of the facial skin from the head, the nose was separated from the rest of the head. A pipette tip was inserted through the pharyngeal opening into the choana, and then two consecutive volumes of 250 Âµl of PBS were gently perfused, and the nostril fluid was collected in a tube. The nasal lavage fluids were centrifuged, and supernatants were stored at â80Â°C until assayed. The isolated nose was cut into two along the midline; the layer of epithelium was mechanically removed from the nasal septum by gently rubbing the sample with a needle under a stereoscopic microscope, and the tissues were then mechanically shredded. Single-cell suspensions containing lymphocytes were isolated by using Lympholyte-M (Cedarlane, Ontario, Canada).</p></sec><sec id="s4-3"><title>ELISA</title><p>ELISA to evaluate antibody binding to the Spike Trimer, RBDs, or NTD was performed by coating Nunc MaxiSorp flat-bottom high-binding 96-half-well plates (Thermo Fisher Scientific, MS, USA) with 50 Î¼l per well of a 0.1 Î¼g/ml protein solution in PBS overnight at 4Â°C. Plates were washed three times with PBS and incubated with 170 Î¼l per well Blocking One solution (Nakarai, Tokyo, Japan) for 1 hr at room temperature. Serially diluted antibody, serum, or nasal lavage fluid was added to PBST (1Ã PBS with 0.1% Tween-20) and incubated for 1 hr at room temperature. The plates were washed three times with PBST and then incubated with anti-mouse IgG or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Abcam, Cambridge, UK) in PBST for 1 hr at room temperature. After washing with PBST three times, the plates were developed by the addition of the SureBlue/TMB peroxidase substrate and stop solution (KPL, MS, USA). Absorbance was measured at 450 nm with an ELISA microplate reader. Protein concentration in serum and nasal lavage fluid is determined by the BCA Protein Assay Kit (TaKaRa, Tokyo, Japan).</p></sec><sec id="s4-4"><title>ACE2 blocking assay</title><p>Nunc MaxiSorp plates were coated with SARS-CoV-2 RBD at 50 ng per well and incubated overnight at 4Â°C. After blocking with Blocking One solution for 1 hr at room temperature, the serially diluted antibody mixed with 5 ng of biotinylated ACE2 in 100 Âµl of PBST was transferred to the plate in triplicate. After incubation for 1 hr at room temperature, the assay plate was washed with PBST three times, and 100 Âµl of streptavidin-HRP (Abcam, Cambridge, UK) diluted 1:5000 in PBST was transferred to each well and incubated for 30 min. After three washes, the plate was developed with streptavidin-HRP and SureBlue/TMB peroxidase substrate.</p></sec><sec id="s4-5"><title>Plasmid construction</title><p>The DNA fragments encoding the human IgA2 constant region, human J-chain, and extracellular domain of human pIgR were amplified by PCR. The IgA2 constant region was replaced with the IgG1 constant region of pJON-mIgG or pETmIgA to make pJON-hIgA and pET-hIgA, respectively (<xref ref-type="bibr" rid="bib24">Kurosawa et al., 2012</xref>). The human J-chain was replaced with the DsRed2 gene of pDsRedN1 (Takara Bio, Shiga, Japan). The pIgR gene was inserted into the pEF-Myc-His vector (Thermo Fisher Scientific, MS, USA).</p></sec><sec id="s4-6"><title>Isolation of antigen-specific plasma cells</title><p>Isolation of antigen-specific plasma cells was performed as described previously with slight modifications (<xref ref-type="bibr" rid="bib24">Kurosawa et al., 2012</xref>). Cells were stained with PE-labeled anti-mouse CD138, DyLight-650-labeled S1, and DyLight488-labeled anti-mouse IgA or anti-mouse IgG at 4Â°C for 30 min with gentle agitation. After washing with PBS, the cells were suspended in PBS containing ER-Tracker Blue-White DPX (ER-Tracker) and subsequently analyzed by FACS. The forward-versus-side-scatter lymphocyte gate (R1) was applied to exclude dead cells. The plasma cells (IgA+ or IgG+, CD138+, ER-Tracker<sup>high</sup>, R2 gate) were further subdivided into fractions according to their binding of DyLight-650-labeled S1 domain of SARS-CoV-2 Spike protein to define antigen-specific plasma cells (IgA+, ER-Tracker<sup>high</sup>, S1+). Single-cell sorting was performed using a JSAN Cell Sorter that was equipped with an automatic cell deposition unit (JSAN, Kobe, Japan) with DyLight488-labeled antibodies against IgA or IgA monitored in the FL-l channel, PE-labeled CD138 in the FL-2 channel, ER-Tracker in the FL-7 channel, and DyLight650-labeled S1 in the FL-6 channel.</p></sec><sec id="s4-7"><title>Monoclonal antibody generation</title><p>Molecular cloning of VH and VL genes from single cells was performed by 5â-RACE PCR as previously described. For the first antibody screening, the PCR-amplified VHa and VL genes were joined to pJON-hIgA and pJON-mIgK to make full-length immunoglobulin alpha heavy and kappa light chain genes by TS-jPCR, respectively (<xref ref-type="bibr" rid="bib48">Yoshioka et al., 2011</xref>). M-IgA was expressed by transfecting a pair of alpha heavy and kappa light chain genes into FreeStyle CHO-S cells that were grown in a 24-well plate according to the manufacturerâs protocol (CHOgro High Yield Expression System, Takara Bio, Shiga, Japan). For large-scale antibody production, the PCR-amplified alpha heavy and kappa light chain genes were inserted into pET-hIgA and pET-mIgK by TS-HR, respectively (<xref ref-type="bibr" rid="bib23">Kurosawa et al., 2011</xref>).</p><p>M-IgA was expressed by cotransfecting plasmids encoding the IgA gene (5 Î¼g) and IgK gene (5 Î¼g) into FreeStyle CHO-S cells (2.0Ã10<sup>5</sup> cells/10 ml). S-IgA was expressed by cotransfecting plasmids encoding the IgA gene (5 Î¼g), IgK gene (5 Î¼g), J-chain (1 Î¼g), and pIgR gene (1 Î¼g) into FreeStyle CHO-S cells (2.0Ã10<sup>5</sup> cells/10 ml). M-IgA was purified by using Peptide M Agarose (Thermo Fisher Scientific). S-IgA was purified by two-step chromatography using the Capturem His-Tagged Purification Kit (Takara Bio, Shiga, Japan) followed by size exclusion chromatography (Cytiva, AKTA go, MS, USA). The purified antibodies were analyzed by SDS-PAGE and native polyacrylamide gel electrophoresis on NuPAGE 4â12% Bis-Tris gels (Thermo Fisher Scientific MS, USA).</p></sec><sec id="s4-8"><title>Antibody binding kinetics by SPR</title><p>The binding kinetics and affinity of monoclonal antibodies to the SARS-CoV-2 spike trimer were analyzed by SPR (Biacore T100, GE Healthcare). Specifically, a biotinylated spike trimer was covalently immobilized to an SA Sensor Chip for a final RU of approximately 200 and interacted with S-IgA containing a mixture of dimers, trimers, and tetramers or M-IgA at various concentrations (0.3, 1.0, 3.0, 9.0, and 27 nM of each antibody). SPR assays were run at a 30 Âµl/min flow rate in HEPES buffer. The dissociation phase was monitored for 5 min. The sensograms were fitted into a two-component model with BIAevaluation software (GE Healthcare).</p></sec><sec id="s4-9"><title>Neutralization activity of monoclonal antibodies against the pseudotyped SARS-CoV-2 virus</title><p>VeroE6/TMPRSS2 cells were incubated with serially diluted antibodies and pseudotyped virus possessing the spike protein of the Wuhan, Delta, Omicron strains or vesicular stomatitis virus and cultured for 48 hr at 37Â°C. After exposure to the virus-antibody mixture, the infectivity of the pseudotyped viruses was determined by measuring the luciferase activities using a PicaGene Luminescence Kit (Fujifilm Wako, Osaka, Japan) with a GloMax Navigator Microplate Luminometer (Promega, WI, USA).</p></sec><sec id="s4-10"><title>Neutralization assay using an authentic virus strain</title><p>The neutralizing activity of monoclonal antibodies against an authentic Wuhan SARS-CoV-2 strain was determined by a neutralization test in a biosafety level 3 laboratory at the Toyama Institute of Health as previously described (<xref ref-type="bibr" rid="bib34">Ozawa et al., 2022</xref>). VeroE6/TMPRSS2 cells plated at 2Ã10<sup>4</sup> cells in each well of 96-well plates were infected with the Wuhan SARS-CoV-2 strain at a multiplicity of infection of 0.001 per cell in the presence of serially twofold diluted monoclonal antibodies for 1 hr. After discarding the culture supernatants, cells were cultured for 24 hr with DMEM containing 10% FBS in the presence of the indicated concentration of monoclonal antibodies. The viral infectious dose was determined by the level of viral genomic RNA in the culture supernatant, which was measured using a real-time PCR assay with a SARS-CoV-2 direct detection RT-qPCR kit (Takara Bio, Siga, Japan). The IC<sub>50</sub> was calculated by IC50 Calculator (<ext-link ext-link-type="uri" xlink:href="https://www.aatbio.com/tools/ic50-calculator">https://www.aatbio.com/tools/ic50-calculator</ext-link>) and represented the neutralization titer.</p></sec><sec id="s4-11"><title>Hamster models</title><p>Six-week-old female Syrian hamsters were purchased from Japan SLC Inc (Shizuoka, Japan). The hamsters were maintained under a 12 hr light-dark cycle and had unrestricted access to food and water in the Division of Animal Resources and Development at the University of Toyama. All animal procedures were approved by the Animal Experiment Committee of the University of Toyama (protocol number: A2023MED-10). Hamsters were intranasally administered 1 mg/kg of IgA in 100 Âµl of PBS (50 Âµl to each nostril) under anesthesia 3 hr before intranasal inoculation of 6.0Ãâ10<sup>5</sup> TCID50 in 100 Âµl of PBS (50 Âµl to each nostril) of SARS-CoV-2 (2019-nCoV/Japan/TY/WK-521/2020) under anesthesia. At 24 and 48 hr after SARS-CoV-2 inoculation, 1 mg/kg of IgA was administered intranasally under anesthesia. Both SARS-CoV-2 inoculation and IgA administration were performed under anesthesia with a mixture of midazolam (2.4 mg/kg) (Maruishi Pharmaceutical Co., Ltd., Osaka, Japan), butorphanol tartrate (3 mg/kg) (Meiji, Tokyo, Japan), and medetomidine hydrochloride (0.18 mg/kg) (ZENOAQ, Fukushima, Japan), and the hamsters were awakened from anesthesia with atipamezole hydrochloride (0.18 mg/kg) (ZENOAQ) after the inoculation or administration. The hamsters were anesthetized and euthanized 72 hr after inoculation with SARS-CoV-2.</p></sec><sec id="s4-12"><title>RNA extraction and real-time RT-PCR</title><p>The nasal turbinates and lungs were collected in ISOGEN (Nippon Gene, Tokyo, Japan) and homogenized with 1.4 mm Ceramic Beads (Thermo Fisher Scientific, Hampton, NH, USA) using BeadMill 24 (Thermo Fisher Scientific) at a speed of 4 m/s for 3 min and stored at â80Â°C until subsequent use. Total RNA was extracted using ISOGEN according to the manufacturerâs instructions. Real-time reverse transcription polymerase chain reaction (RT-PCR) was performed by amplifying the SARS-CoV-2 N2 gene using QuantStudio 6 Pro Real-Time PCR System (Thermo Fisher Scientific) and THUNDERBIRD Probe One-step qRT-PCR Kit (TOYOBO, Osaka, Japan) with the N2 primer/probe set (Nihon Gene Research Laboratories, Miyagi, Japan). The absolute copy number of the SARS-CoV-2 N2 gene was determined by serial dilution of RNA control (Nihon Gene Research Laboratories).</p></sec><sec id="s4-13"><title>Gene family and phylogenetic analysis of monoclonal antibodies</title><p>The antibody sequences were annotated against the IMGT mouse heavy and light chain gene database using NCBI IgBlast to determine IGHV, IGHD, IGLV, IGHJ, IGLV, and IGLJ gene annotations. Antibody clones were assigned to clonal groups using Sequencher software. The heavy and light chain variable gene arrangement and phylogenetic analyses were performed using MAFFT, a multiple alignment program, in the GENETYX sequence analysis package (<ext-link ext-link-type="uri" xlink:href="https://www.genetyx.co.jp">https://www.genetyx.co.jp</ext-link>). For SHM, IGHV and IGLV sequences were aligned against representative clones of each group. Antibody clones consisting of pairs of heavy and light chain variable genes (signal sequence to FW4) were used to generate an antibody phylogenetic tree. Full-length germline sequences were reconstructed, with nucleotide additions/deletions in the junction between V-(D)-J adjusted to match the sequence of each antibody group. Within these groups, if the combined sequence of the heavy and light chains differed by more than five bases from each other, they were defined as separate clones. The sequence alignment tool Clustal Omega (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/Tools/msa/clustalo/">https://www.ebi.ac.uk/Tools/msa/clustalo/</ext-link>) was used to identify deletions and insertions and to align the length of the sequence. The nucleotide lengths were aligned by adding â-â to the missing bases. The data file required by Alakazam was created in RStudio (version 2022.12.0+353), and a phylogenetic tree was created by Alakazam (<ext-link ext-link-type="uri" xlink:href="https://www.rdocumentation.org/packages/alakazam/versions/1.2.1">https://www.rdocumentation.org/packages/alakazam/versions/1.2.1</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://alakazam.readthedocs.io/en/stable/">https://alakazam.readthedocs.io/en/stable/</ext-link>). The R script was as follows: <ext-link ext-link-type="uri" xlink:href="https://www.rdocumentation.org/packages/alakazam/versions/1.2.1/topics/buildPhylipLineage">https://www.rdocumentation.org/packages/alakazam/versions/1.2.1/topics/buildPhylipLineage</ext-link>.</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>All statistical analyses were performed using JMP statistical software (JMP Statistical Discovery, NC, USA). Unpaired Studentâs t-tests were used to analyze each dataset. The threshold for statistical significance was set at p&lt;0.01 (**).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experiments were performed in accordance with relevant guidelines and regulations. The Committee on Animal Experimentation at the University of Toyama approved the animal experimental protocols, which were conducted using project license A2017eng-1.All experiments involving live SARS-CoV-2 followed the approved standard operating procedures in the Biosafety Level 3 facility at the University of Toyama and Toyama Institute of Health.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Nucleotide sequences of antigen-specific antibodies and their V-(D)-J usage.</title><p>Antibody sequences are organized by clone name, class, type, and group. The nucleotide sequences of the variable domains of the heavy and light chains are analyzed using IMGT/HighV-QUEST, and the best-matched IMGT reference germline alleles are provided. The somatic hypermutation (SHM) status is evaluated based on the number of mutations present in the sequences of the heavy and light chain variable domains.</p></caption><media xlink:href="elife-88387-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88387-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. The nucleotide sequence data are available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and have been submitted to the DDBJ/EMBL/GenBank databases (accession numbers <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761310/">LC761310</ext-link>â<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761361/">LC761361</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761441/">LC761441</ext-link>â<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761570/">LC761570</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761965/">LC761965</ext-link>â<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC762059/">LC762059</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC764607/">LC764607</ext-link>â<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC764701/">LC764701</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761389/">LC761389</ext-link>â<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LC761570/">LC761570</ext-link>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank past and current members of our laboratory for fruitful discussions. We also thank M Nozaki and K Takai for technical support. This research was supported by grants from the Japan Agency for Medical Research and Development (AMED) (19187977, 20333128, and 22723616) and The Toyama Pharmaceutical Valley Development Consortium (no grant number assigned) to Masaharu Isobe and Japan Society for the Promotion of Science, Japan (Grant in Aid for Scientific Research B) (22H02875) to Nobuyuki Kurosawa. The funders had no role in the study design, data collection, and analysis, publishing decisions, or the preparation of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>DâAgostino</surname><given-names>MR</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Stacey</surname><given-names>HD</given-names></name><name><surname>Marzok</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Bavananthasivam</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ang</surname><given-names>JC</given-names></name><name><surname>Zganiacz</surname><given-names>A</given-names></name><name><surname>Sankar</surname><given-names>U</given-names></name><name><surname>Kazhdan</surname><given-names>N</given-names></name><name><surname>Koenig</surname><given-names>JFE</given-names></name><name><surname>Phelps</surname><given-names>A</given-names></name><name><surname>Gameiro</surname><given-names>SF</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Jordana</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Mossman</surname><given-names>KL</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Gillgrass</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>MFC</given-names></name><name><surname>Smaill</surname><given-names>F</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Miller</surname><given-names>MS</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2</article-title><source>Cell</source><volume>185</volume><fpage>896</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.02.005</pub-id><pub-id pub-id-type="pmid">35180381</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alu</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Intranasal COVID-19 vaccines: from bench to bed</article-title><source>EBioMedicine</source><volume>76</volume><elocation-id>103841</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103841</pub-id><pub-id pub-id-type="pmid">35085851</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahi</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>I</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Nanno</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Ohwaki</surname><given-names>M</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>C</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines</article-title><source>Journal of Immunology</source><volume>168</volume><fpage>2930</fpage><lpage>2938</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.6.2930</pub-id><pub-id pub-id-type="pmid">11884464</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahi-Ozaki</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>S-I</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus</article-title><source>Journal of Medical Virology</source><volume>74</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1002/jmv.20173</pub-id><pub-id pub-id-type="pmid">15332283</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzi</surname><given-names>L</given-names></name><name><surname>Dalla Gasperina</surname><given-names>D</given-names></name><name><surname>Veronesi</surname><given-names>G</given-names></name><name><surname>Shallak</surname><given-names>M</given-names></name><name><surname>Ietto</surname><given-names>G</given-names></name><name><surname>Iovino</surname><given-names>D</given-names></name><name><surname>Baj</surname><given-names>A</given-names></name><name><surname>Gianfagna</surname><given-names>F</given-names></name><name><surname>Maurino</surname><given-names>V</given-names></name><name><surname>Focosi</surname><given-names>D</given-names></name><name><surname>Maggi</surname><given-names>F</given-names></name><name><surname>Ferrario</surname><given-names>MM</given-names></name><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Carcano</surname><given-names>G</given-names></name><name><surname>Tagliabue</surname><given-names>A</given-names></name><name><surname>Maffioli</surname><given-names>LS</given-names></name><name><surname>Accolla</surname><given-names>RS</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mucosal immune response in BNT162b2 COVID-19 vaccine recipients</article-title><source>EBioMedicine</source><volume>75</volume><elocation-id>103788</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103788</pub-id><pub-id pub-id-type="pmid">34954658</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JR</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Ewer</surname><given-names>KJ</given-names></name><name><surname>Folegatti</surname><given-names>PM</given-names></name><name><surname>Gilbride</surname><given-names>C</given-names></name><name><surname>Halkerston</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Jenkin</surname><given-names>D</given-names></name><name><surname>Stockdale</surname><given-names>L</given-names></name><name><surname>Verheul</surname><given-names>MK</given-names></name><name><surname>Aley</surname><given-names>PK</given-names></name><name><surname>Angus</surname><given-names>B</given-names></name><name><surname>Bellamy</surname><given-names>D</given-names></name><name><surname>Berrie</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Cavell</surname><given-names>B</given-names></name><name><surname>Clutterbuck</surname><given-names>EA</given-names></name><name><surname>Edwards</surname><given-names>N</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Fuskova</surname><given-names>M</given-names></name><name><surname>Gorringe</surname><given-names>A</given-names></name><name><surname>Hallis</surname><given-names>B</given-names></name><name><surname>Kerridge</surname><given-names>S</given-names></name><name><surname>Lawrie</surname><given-names>AM</given-names></name><name><surname>Linder</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Madhavan</surname><given-names>M</given-names></name><name><surname>Makinson</surname><given-names>R</given-names></name><name><surname>Mellors</surname><given-names>J</given-names></name><name><surname>Minassian</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Mujadidi</surname><given-names>Y</given-names></name><name><surname>Plested</surname><given-names>E</given-names></name><name><surname>Poulton</surname><given-names>I</given-names></name><name><surname>Ramasamy</surname><given-names>MN</given-names></name><name><surname>Robinson</surname><given-names>H</given-names></name><name><surname>Rollier</surname><given-names>CS</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Snape</surname><given-names>MD</given-names></name><name><surname>Tarrant</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>KM</given-names></name><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>MEE</given-names></name><name><surname>Wright</surname><given-names>D</given-names></name><name><surname>Douglas</surname><given-names>AD</given-names></name><name><surname>Green</surname><given-names>CM</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Aboagye</surname><given-names>J</given-names></name><name><surname>Alderson</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>L</given-names></name><name><surname>Anslow</surname><given-names>R</given-names></name><name><surname>Arancibia-CÃ¡rcamo</surname><given-names>CV</given-names></name><name><surname>Arbe-Barnes</surname><given-names>EH</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Baleanu</surname><given-names>I</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Bates</surname><given-names>L</given-names></name><name><surname>Batten</surname><given-names>A</given-names></name><name><surname>Beadon</surname><given-names>K</given-names></name><name><surname>Beckley</surname><given-names>R</given-names></name><name><surname>Beveridge</surname><given-names>A</given-names></name><name><surname>Bewley</surname><given-names>KR</given-names></name><name><surname>Bijker</surname><given-names>EM</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><name><surname>Blundell</surname><given-names>CL</given-names></name><name><surname>Bolam</surname><given-names>E</given-names></name><name><surname>Boland</surname><given-names>E</given-names></name><name><surname>Borthwick</surname><given-names>N</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Brown-OâSullivan</surname><given-names>C</given-names></name><name><surname>Brunt</surname><given-names>E</given-names></name><name><surname>Burbage</surname><given-names>J</given-names></name><name><surname>Buttigieg</surname><given-names>KR</given-names></name><name><surname>Byard</surname><given-names>N</given-names></name><name><surname>Cabrera Puig</surname><given-names>I</given-names></name><name><surname>Camara</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Cappuccini</surname><given-names>F</given-names></name><name><surname>Carr</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Chadwick</surname><given-names>J</given-names></name><name><surname>Chelysheva</surname><given-names>I</given-names></name><name><surname>Cho</surname><given-names>JS</given-names></name><name><surname>Cifuentes</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Colin-Jones</surname><given-names>R</given-names></name><name><surname>Conlon</surname><given-names>CP</given-names></name><name><surname>Coombes</surname><given-names>NS</given-names></name><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Crocker</surname><given-names>WEM</given-names></name><name><surname>Cunningham</surname><given-names>CJ</given-names></name><name><surname>Damratoski</surname><given-names>BE</given-names></name><name><surname>Datoo</surname><given-names>MS</given-names></name><name><surname>Datta</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Demissie</surname><given-names>T</given-names></name><name><surname>Di Maso</surname><given-names>C</given-names></name><name><surname>DiTirro</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Donnellan</surname><given-names>FR</given-names></name><name><surname>Douglas</surname><given-names>N</given-names></name><name><surname>Downing</surname><given-names>C</given-names></name><name><surname>Drake</surname><given-names>J</given-names></name><name><surname>Drake-Brockman</surname><given-names>R</given-names></name><name><surname>Drury</surname><given-names>RE</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Muhanna</surname><given-names>OE</given-names></name><name><surname>Elias</surname><given-names>SC</given-names></name><name><surname>Elmore</surname><given-names>MJ</given-names></name><name><surname>Emary</surname><given-names>KRW</given-names></name><name><surname>English</surname><given-names>MR</given-names></name><name><surname>Felle</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Da Silva</surname><given-names>CF</given-names></name><name><surname>Field</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>KJ</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>E</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><name><surname>Furze</surname><given-names>J</given-names></name><name><surname>Galian-Rubio</surname><given-names>P</given-names></name><name><surname>Garlant</surname><given-names>H</given-names></name><name><surname>Godwin</surname><given-names>K</given-names></name><name><surname>Gorini</surname><given-names>G</given-names></name><name><surname>Gracie</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Hamilton</surname><given-names>E</given-names></name><name><surname>Hamlyn</surname><given-names>J</given-names></name><name><surname>Hanumunthadu</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>SA</given-names></name><name><surname>Harrison</surname><given-names>D</given-names></name><name><surname>Hart</surname><given-names>TC</given-names></name><name><surname>Hawkins</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>JA</given-names></name><name><surname>Hodges</surname><given-names>G</given-names></name><name><surname>Hodgson</surname><given-names>SHC</given-names></name><name><surname>Hou</surname><given-names>MM</given-names></name><name><surname>Howe</surname><given-names>E</given-names></name><name><surname>Howell</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Humphries</surname><given-names>H</given-names></name><name><surname>Iveson</surname><given-names>P</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>F</given-names></name><name><surname>Jauregui</surname><given-names>S</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Kailath</surname><given-names>R</given-names></name><name><surname>Keen</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>E</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Khan</surname><given-names>L</given-names></name><name><surname>Khozoee</surname><given-names>B</given-names></name><name><surname>Killen</surname><given-names>A</given-names></name><name><surname>Kinch</surname><given-names>J</given-names></name><name><surname>King</surname><given-names>TB</given-names></name><name><surname>King</surname><given-names>L</given-names></name><name><surname>Kingham-Page</surname><given-names>L</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Knott</surname><given-names>D</given-names></name><name><surname>Koleva</surname><given-names>S</given-names></name><name><surname>Larkworthy</surname><given-names>CW</given-names></name><name><surname>Larwood</surname><given-names>JPJ</given-names></name><name><surname>Lees</surname><given-names>EA</given-names></name><name><surname>Lelliott</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lias</surname><given-names>AM</given-names></name><name><surname>Lipworth</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Loew</surname><given-names>L</given-names></name><name><surname>Lopez Ramon</surname><given-names>R</given-names></name><name><surname>Mallett</surname><given-names>G</given-names></name><name><surname>Mansatta</surname><given-names>K</given-names></name><name><surname>Marchevsky</surname><given-names>NG</given-names></name><name><surname>Marinou</surname><given-names>S</given-names></name><name><surname>Marlow</surname><given-names>E</given-names></name><name><surname>Marshall</surname><given-names>JL</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>McEwan</surname><given-names>J</given-names></name><name><surname>McGlashan</surname><given-names>J</given-names></name><name><surname>McInroy</surname><given-names>L</given-names></name><name><surname>Meddaugh</surname><given-names>G</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Mirtorabi</surname><given-names>N</given-names></name><name><surname>Morey</surname><given-names>E</given-names></name><name><surname>Morgans</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>SJ</given-names></name><name><surname>Morrison</surname><given-names>H</given-names></name><name><surname>Morshead</surname><given-names>G</given-names></name><name><surname>Morter</surname><given-names>R</given-names></name><name><surname>Moya</surname><given-names>N</given-names></name><name><surname>Mukhopadhyay</surname><given-names>E</given-names></name><name><surname>Muller</surname><given-names>J</given-names></name><name><surname>Munro</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name><name><surname>Mweu</surname><given-names>P</given-names></name><name><surname>NoÃ©</surname><given-names>A</given-names></name><name><surname>Nugent</surname><given-names>FL</given-names></name><name><surname>Nuthall</surname><given-names>E</given-names></name><name><surname>OâBrien</surname><given-names>K</given-names></name><name><surname>OâConnor</surname><given-names>D</given-names></name><name><surname>OâDonnell</surname><given-names>D</given-names></name><name><surname>Oguti</surname><given-names>B</given-names></name><name><surname>Olchawski</surname><given-names>V</given-names></name><name><surname>Oliveria</surname><given-names>C</given-names></name><name><surname>OâReilly</surname><given-names>PJ</given-names></name><name><surname>Osborne</surname><given-names>P</given-names></name><name><surname>Owino</surname><given-names>N</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><name><surname>Parracho</surname><given-names>H</given-names></name><name><surname>Patrick-Smith</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Penn</surname><given-names>E</given-names></name><name><surname>Peralta Alvarez</surname><given-names>MP</given-names></name><name><surname>Perring</surname><given-names>J</given-names></name><name><surname>Petropoulos</surname><given-names>C</given-names></name><name><surname>Pfafferott</surname><given-names>K</given-names></name><name><surname>Pipini</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Proud</surname><given-names>P</given-names></name><name><surname>Provstgaard-Morys</surname><given-names>S</given-names></name><name><surname>Pulido</surname><given-names>D</given-names></name><name><surname>Radia</surname><given-names>K</given-names></name><name><surname>Rajapaksa</surname><given-names>D</given-names></name><name><surname>Ramos Lopez</surname><given-names>F</given-names></name><name><surname>Ratcliffe</surname><given-names>H</given-names></name><name><surname>Rawlinson</surname><given-names>T</given-names></name><name><surname>Pabon</surname><given-names>ER</given-names></name><name><surname>Rhead</surname><given-names>S</given-names></name><name><surname>Ritchie</surname><given-names>AJ</given-names></name><name><surname>Roberts</surname><given-names>H</given-names></name><name><surname>Roche</surname><given-names>S</given-names></name><name><surname>Rudiansyah</surname><given-names>I</given-names></name><name><surname>Salvador</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>H</given-names></name><name><surname>Sanders</surname><given-names>K</given-names></name><name><surname>Satti</surname><given-names>I</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Schofield</surname><given-names>E</given-names></name><name><surname>Screaton</surname><given-names>G</given-names></name><name><surname>Sedik</surname><given-names>C</given-names></name><name><surname>Shaik</surname><given-names>I</given-names></name><name><surname>Sharpe</surname><given-names>HR</given-names></name><name><surname>Shea</surname><given-names>A</given-names></name><name><surname>Silk</surname><given-names>S</given-names></name><name><surname>Silva-Reyes</surname><given-names>L</given-names></name><name><surname>Skelly</surname><given-names>DT</given-names></name><name><surname>Smith</surname><given-names>CC</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Spencer</surname><given-names>AJ</given-names></name><name><surname>Stafford</surname><given-names>E</given-names></name><name><surname>Szigeti</surname><given-names>A</given-names></name><name><surname>Tahiri-Alaoui</surname><given-names>A</given-names></name><name><surname>Tanner</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>IJ</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>te Water Naude</surname><given-names>R</given-names></name><name><surname>Themistocleous</surname><given-names>Y</given-names></name><name><surname>Themistocleous</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>TM</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Tinh</surname><given-names>L</given-names></name><name><surname>Tomic</surname><given-names>A</given-names></name><name><surname>Tonks</surname><given-names>S</given-names></name><name><surname>Towner</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Tree</surname><given-names>JA</given-names></name><name><surname>Truby</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Ulaszewska</surname><given-names>M</given-names></name><name><surname>Varughese</surname><given-names>R</given-names></name><name><surname>Vichos</surname><given-names>I</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Wand</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>P</given-names></name><name><surname>Worth</surname><given-names>AT</given-names></name><name><surname>Wrin</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>XL</given-names></name><name><surname>Zizi</surname><given-names>D</given-names></name><collab>the Oxford COVID Vaccine Trial Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses</article-title><source>Nature Medicine</source><volume>27</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01179-4</pub-id><pub-id pub-id-type="pmid">33335322</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bricker</surname><given-names>TL</given-names></name><name><surname>Darling</surname><given-names>TL</given-names></name><name><surname>Hassan</surname><given-names>AO</given-names></name><name><surname>Harastani</surname><given-names>HH</given-names></name><name><surname>Soung</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>XP</given-names></name><name><surname>Dai</surname><given-names>YN</given-names></name><name><surname>Zhao</surname><given-names>HY</given-names></name><name><surname>Adams</surname><given-names>LJ</given-names></name><name><surname>Holtzman</surname><given-names>MJ</given-names></name><name><surname>Bailey</surname><given-names>AL</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Boon</surname><given-names>ACM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters</article-title><source>Cell Reports</source><volume>36</volume><elocation-id>109400</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109400</pub-id><pub-id pub-id-type="pmid">34245672</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budinger</surname><given-names>GRS</given-names></name><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Ridge</surname><given-names>KM</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Distinctive features of severe SARS-CoV-2 pneumonia</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>MC8279580</elocation-id><pub-id pub-id-type="doi">10.1172/JCI149412</pub-id><pub-id pub-id-type="pmid">34263736</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callegari</surname><given-names>I</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Berloffa</surname><given-names>G</given-names></name><name><surname>MÃ¼hlethaler</surname><given-names>T</given-names></name><name><surname>Holdermann</surname><given-names>S</given-names></name><name><surname>Galli</surname><given-names>E</given-names></name><name><surname>Roloff</surname><given-names>T</given-names></name><name><surname>Boss</surname><given-names>R</given-names></name><name><surname>Infanti</surname><given-names>L</given-names></name><name><surname>Khanna</surname><given-names>N</given-names></name><name><surname>Egli</surname><given-names>A</given-names></name><name><surname>Buser</surname><given-names>A</given-names></name><name><surname>Zimmer</surname><given-names>G</given-names></name><name><surname>Derfuss</surname><given-names>T</given-names></name><name><surname>Sanderson</surname><given-names>NSR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch</article-title><source>EMBO Reports</source><volume>23</volume><elocation-id>e53956</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202153956</pub-id><pub-id pub-id-type="pmid">35548920</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavda</surname><given-names>VP</given-names></name><name><surname>Vora</surname><given-names>LK</given-names></name><name><surname>Pandya</surname><given-names>AK</given-names></name><name><surname>Patravale</surname><given-names>VB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management</article-title><source>Drug Discovery Today</source><volume>26</volume><fpage>2619</fpage><lpage>2636</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2021.07.021</pub-id><pub-id pub-id-type="pmid">34332100</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DâArco</surname><given-names>C</given-names></name><name><surname>McCormick</surname><given-names>AA</given-names></name><name><surname>Arnaboldi</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection</article-title><source>Vaccine</source><volume>39</volume><fpage>1435</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.040</pub-id><pub-id pub-id-type="pmid">33531196</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFrancesco</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 antibodies on trial</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>1242</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0732-8</pub-id><pub-id pub-id-type="pmid">33087898</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhakal</surname><given-names>S</given-names></name><name><surname>Renu</surname><given-names>S</given-names></name><name><surname>Ghimire</surname><given-names>S</given-names></name><name><surname>Shaan Lakshmanappa</surname><given-names>Y</given-names></name><name><surname>Hogshead</surname><given-names>BT</given-names></name><name><surname>Feliciano-Ruiz</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>HogenEsch</surname><given-names>H</given-names></name><name><surname>Krakowka</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Renukaradhya</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>934</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00934</pub-id><pub-id pub-id-type="pmid">29770135</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ejemel</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Schiller</surname><given-names>ZA</given-names></name><name><surname>Tree</surname><given-names>JA</given-names></name><name><surname>Wallace</surname><given-names>A</given-names></name><name><surname>Amcheslavsky</surname><given-names>A</given-names></name><name><surname>Kurt Yilmaz</surname><given-names>N</given-names></name><name><surname>Buttigieg</surname><given-names>KR</given-names></name><name><surname>Elmore</surname><given-names>MJ</given-names></name><name><surname>Godwin</surname><given-names>K</given-names></name><name><surname>Coombes</surname><given-names>N</given-names></name><name><surname>Toomey</surname><given-names>JR</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Ramchetty</surname><given-names>AS</given-names></name><name><surname>Close</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>DY</given-names></name><name><surname>Conway</surname><given-names>HL</given-names></name><name><surname>Saeed</surname><given-names>M</given-names></name><name><surname>Ganesa</surname><given-names>C</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Cavacini</surname><given-names>LA</given-names></name><name><surname>Klempner</surname><given-names>MS</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4198</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18058-8</pub-id><pub-id pub-id-type="pmid">32826914</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewer</surname><given-names>KJ</given-names></name><name><surname>Barrett</surname><given-names>JR</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Sharpe</surname><given-names>H</given-names></name><name><surname>Makinson</surname><given-names>R</given-names></name><name><surname>Morter</surname><given-names>R</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>D</given-names></name><name><surname>Bellamy</surname><given-names>D</given-names></name><name><surname>Bittaye</surname><given-names>M</given-names></name><name><surname>Dold</surname><given-names>C</given-names></name><name><surname>Provine</surname><given-names>NM</given-names></name><name><surname>Aboagye</surname><given-names>J</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Silk</surname><given-names>SE</given-names></name><name><surname>Alderson</surname><given-names>J</given-names></name><name><surname>Aley</surname><given-names>PK</given-names></name><name><surname>Angus</surname><given-names>B</given-names></name><name><surname>Berrie</surname><given-names>E</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><name><surname>Cicconi</surname><given-names>P</given-names></name><name><surname>Clutterbuck</surname><given-names>EA</given-names></name><name><surname>Chelysheva</surname><given-names>I</given-names></name><name><surname>Folegatti</surname><given-names>PM</given-names></name><name><surname>Fuskova</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>CM</given-names></name><name><surname>Jenkin</surname><given-names>D</given-names></name><name><surname>Kerridge</surname><given-names>S</given-names></name><name><surname>Lawrie</surname><given-names>A</given-names></name><name><surname>Minassian</surname><given-names>AM</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Mujadidi</surname><given-names>Y</given-names></name><name><surname>Plested</surname><given-names>E</given-names></name><name><surname>Poulton</surname><given-names>I</given-names></name><name><surname>Ramasamy</surname><given-names>MN</given-names></name><name><surname>Robinson</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Snape</surname><given-names>MD</given-names></name><name><surname>Tarrant</surname><given-names>R</given-names></name><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>MEE</given-names></name><name><surname>Douglas</surname><given-names>AD</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Borthwick</surname><given-names>N</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Brown-OâSullivan</surname><given-names>C</given-names></name><name><surname>Burgoyne</surname><given-names>J</given-names></name><name><surname>Byard</surname><given-names>N</given-names></name><name><surname>Puig</surname><given-names>IC</given-names></name><name><surname>Cappuccini</surname><given-names>F</given-names></name><name><surname>Cho</surname><given-names>JS</given-names></name><name><surname>Cicconi</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Crocker</surname><given-names>WEM</given-names></name><name><surname>Datoo</surname><given-names>MS</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Donnellan</surname><given-names>FR</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Elias</surname><given-names>SC</given-names></name><name><surname>Furze</surname><given-names>J</given-names></name><name><surname>Gilbride</surname><given-names>C</given-names></name><name><surname>Gorini</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>SA</given-names></name><name><surname>Hodgson</surname><given-names>SHC</given-names></name><name><surname>Hou</surname><given-names>MM</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Kailath</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>L</given-names></name><name><surname>Larkworthy</surname><given-names>CW</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lias</surname><given-names>AM</given-names></name><name><surname>Linder</surname><given-names>A</given-names></name><name><surname>Lipworth</surname><given-names>S</given-names></name><name><surname>Ramon</surname><given-names>RL</given-names></name><name><surname>Madhavan</surname><given-names>M</given-names></name><name><surname>Marlow</surname><given-names>E</given-names></name><name><surname>Marshall</surname><given-names>JL</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Morrison</surname><given-names>H</given-names></name><name><surname>Moya</surname><given-names>N</given-names></name><name><surname>Mukhopadhyay</surname><given-names>E</given-names></name><name><surname>NoÃ©</surname><given-names>A</given-names></name><name><surname>Nugent</surname><given-names>FL</given-names></name><name><surname>Pipini</surname><given-names>D</given-names></name><name><surname>Pulido-Gomez</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>FR</given-names></name><name><surname>Ritchie</surname><given-names>AJ</given-names></name><name><surname>Rudiansyah</surname><given-names>I</given-names></name><name><surname>Salvador</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>H</given-names></name><name><surname>Satti</surname><given-names>I</given-names></name><name><surname>Shea</surname><given-names>A</given-names></name><name><surname>Silk</surname><given-names>S</given-names></name><name><surname>Spencer</surname><given-names>AJ</given-names></name><name><surname>Tanner</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>IJ</given-names></name><name><surname>Themistocleous</surname><given-names>Y</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Truby</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Ulaszewska</surname><given-names>M</given-names></name><name><surname>Worth</surname><given-names>AT</given-names></name><name><surname>Kingham-Page</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>MPP</given-names></name><name><surname>Anslow</surname><given-names>R</given-names></name><name><surname>Bates</surname><given-names>L</given-names></name><name><surname>Beadon</surname><given-names>K</given-names></name><name><surname>Beckley</surname><given-names>R</given-names></name><name><surname>Beveridge</surname><given-names>A</given-names></name><name><surname>Bijker</surname><given-names>EM</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><name><surname>Burbage</surname><given-names>J</given-names></name><name><surname>Camara</surname><given-names>S</given-names></name><name><surname>Carr</surname><given-names>M</given-names></name><name><surname>Colin-Jones</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Cunningham</surname><given-names>CJ</given-names></name><name><surname>Demissie</surname><given-names>T</given-names></name><name><surname>Maso</surname><given-names>CD</given-names></name><name><surname>Douglas</surname><given-names>N</given-names></name><name><surname>Drake-Brockman</surname><given-names>R</given-names></name><name><surname>Drury</surname><given-names>RE</given-names></name><name><surname>Emary</surname><given-names>KRW</given-names></name><name><surname>Felle</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>CFD</given-names></name><name><surname>Ford</surname><given-names>KJ</given-names></name><name><surname>Francis</surname><given-names>E</given-names></name><name><surname>Gracie</surname><given-names>L</given-names></name><name><surname>Hamlyn</surname><given-names>J</given-names></name><name><surname>Hanumunthadu</surname><given-names>B</given-names></name><name><surname>Harrison</surname><given-names>D</given-names></name><name><surname>Hart</surname><given-names>TC</given-names></name><name><surname>Hawkins</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Howe</surname><given-names>E</given-names></name><name><surname>Howell</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Keen</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Khan</surname><given-names>L</given-names></name><name><surname>Kinch</surname><given-names>J</given-names></name><name><surname>Koleva</surname><given-names>S</given-names></name><name><surname>Lees</surname><given-names>EA</given-names></name><name><surname>Lelliott</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Marchevsky</surname><given-names>NG</given-names></name><name><surname>Marinou</surname><given-names>S</given-names></name><name><surname>McEwan</surname><given-names>J</given-names></name><name><surname>Morey</surname><given-names>E</given-names></name><name><surname>Morshead</surname><given-names>G</given-names></name><name><surname>Muller</surname><given-names>J</given-names></name><name><surname>Munro</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name><name><surname>Mweu</surname><given-names>P</given-names></name><name><surname>Nuthall</surname><given-names>E</given-names></name><name><surname>OâBrien</surname><given-names>K</given-names></name><name><surname>OâConnor</surname><given-names>D</given-names></name><name><surname>OâReilly</surname><given-names>PJ</given-names></name><name><surname>Oguti</surname><given-names>B</given-names></name><name><surname>Osborne</surname><given-names>P</given-names></name><name><surname>Owino</surname><given-names>N</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><name><surname>Pfafferott</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Provstgaard-Morys</surname><given-names>S</given-names></name><name><surname>Ratcliffe</surname><given-names>H</given-names></name><name><surname>Rawlinson</surname><given-names>T</given-names></name><name><surname>Rhead</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>H</given-names></name><name><surname>Sanders</surname><given-names>K</given-names></name><name><surname>Silva-Reyes</surname><given-names>L</given-names></name><name><surname>Rollier</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>CC</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Stockdale</surname><given-names>L</given-names></name><name><surname>Szigeti</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>TM</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Tomic</surname><given-names>A</given-names></name><name><surname>Tonks</surname><given-names>S</given-names></name><name><surname>Varughese</surname><given-names>R</given-names></name><name><surname>Verheul</surname><given-names>MK</given-names></name><name><surname>Vichos</surname><given-names>I</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>XL</given-names></name><name><surname>Conlon</surname><given-names>CP</given-names></name><name><surname>Frater</surname><given-names>J</given-names></name><name><surname>Cifuentes</surname><given-names>L</given-names></name><name><surname>Baleanu</surname><given-names>I</given-names></name><name><surname>Bolam</surname><given-names>E</given-names></name><name><surname>Boland</surname><given-names>E</given-names></name><name><surname>Brenner</surname><given-names>T</given-names></name><name><surname>Damratoski</surname><given-names>BE</given-names></name><name><surname>Datta</surname><given-names>C</given-names></name><name><surname>Muhanna</surname><given-names>OE</given-names></name><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Galian-Rubio</surname><given-names>P</given-names></name><name><surname>Hodges</surname><given-names>G</given-names></name><name><surname>Jackson</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Loew</surname><given-names>L</given-names></name><name><surname>Morgans</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>SJ</given-names></name><name><surname>Olchawski</surname><given-names>V</given-names></name><name><surname>Oliveria</surname><given-names>C</given-names></name><name><surname>Parracho</surname><given-names>H</given-names></name><name><surname>Pabon</surname><given-names>ER</given-names></name><name><surname>Tahiri-Alaoui</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>P</given-names></name><name><surname>Zizi</surname><given-names>D</given-names></name><name><surname>Arbe-Barnes</surname><given-names>EH</given-names></name><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Batten</surname><given-names>A</given-names></name><name><surname>Downing</surname><given-names>C</given-names></name><name><surname>Drake</surname><given-names>J</given-names></name><name><surname>English</surname><given-names>MR</given-names></name><name><surname>Henry</surname><given-names>JA</given-names></name><name><surname>Iveson</surname><given-names>P</given-names></name><name><surname>Killen</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>TB</given-names></name><name><surname>Larwood</surname><given-names>JPJ</given-names></name><name><surname>Mallett</surname><given-names>G</given-names></name><name><surname>Mansatta</surname><given-names>K</given-names></name><name><surname>Mirtorabi</surname><given-names>N</given-names></name><name><surname>Patrick-Smith</surname><given-names>M</given-names></name><name><surname>Perring</surname><given-names>J</given-names></name><name><surname>Radia</surname><given-names>K</given-names></name><name><surname>Roche</surname><given-names>S</given-names></name><name><surname>Schofield</surname><given-names>E</given-names></name><name><surname>Naude</surname><given-names>RW</given-names></name><name><surname>Towner</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Bewley</surname><given-names>KR</given-names></name><name><surname>Brunt</surname><given-names>E</given-names></name><name><surname>Buttigieg</surname><given-names>KR</given-names></name><name><surname>Carroll</surname><given-names>MW</given-names></name><name><surname>Charlton</surname><given-names>S</given-names></name><name><surname>Coombes</surname><given-names>NS</given-names></name><name><surname>Elmore</surname><given-names>MJ</given-names></name><name><surname>Godwin</surname><given-names>K</given-names></name><name><surname>Hallis</surname><given-names>B</given-names></name><name><surname>Knott</surname><given-names>D</given-names></name><name><surname>McInroy</surname><given-names>L</given-names></name><name><surname>Shaik</surname><given-names>I</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Tree</surname><given-names>JA</given-names></name><name><surname>Blundell</surname><given-names>CL</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Skelly</surname><given-names>DT</given-names></name><name><surname>Themistocleous</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Field</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>E</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Lie</surname><given-names>Y</given-names></name><name><surname>Petropoulos</surname><given-names>C</given-names></name><name><surname>Sedik</surname><given-names>C</given-names></name><name><surname>Wrin</surname><given-names>T</given-names></name><name><surname>Meddaugh</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Screaton</surname><given-names>G</given-names></name><name><surname>Stafford</surname><given-names>E</given-names></name><collab>the Oxford COVID Vaccine Trial Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title><source>Nature Medicine</source><volume>27</volume><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galimidi</surname><given-names>RP</given-names></name><name><surname>Klein</surname><given-names>JS</given-names></name><name><surname>Politzer</surname><given-names>MS</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intra-spike crosslinking overcomes antibody evasion by HIV-1</article-title><source>Cell</source><volume>160</volume><fpage>433</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.01.016</pub-id><pub-id pub-id-type="pmid">25635457</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianchecchi</surname><given-names>E</given-names></name><name><surname>Manenti</surname><given-names>A</given-names></name><name><surname>Kistner</surname><given-names>O</given-names></name><name><surname>Trombetta</surname><given-names>C</given-names></name><name><surname>Manini</surname><given-names>I</given-names></name><name><surname>Montomoli</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions</article-title><source>Influenza and Other Respiratory Viruses</source><volume>13</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1111/irv.12664</pub-id><pub-id pub-id-type="pmid">31225704</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>K</given-names></name><name><surname>Takai-Todaka</surname><given-names>R</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Tojo</surname><given-names>T</given-names></name><name><surname>Nagami</surname><given-names>A</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Masaki</surname><given-names>H</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Ebisudani</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>H</given-names></name><name><surname>Fukunaga</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>A</given-names></name><name><surname>Nemoto</surname><given-names>N</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Morimoto</surname><given-names>T</given-names></name><name><surname>Katayama</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model</article-title><source>PLOS Pathogens</source><volume>17</volume><elocation-id>e1009542</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009542</pub-id><pub-id pub-id-type="pmid">34648602</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 mucosal vaccine</article-title><source>Nature Immunology</source><volume>24</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1038/s41590-022-01405-w</pub-id><pub-id pub-id-type="pmid">36596900</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>23</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Weisel</surname><given-names>FJ</given-names></name><name><surname>Balmert</surname><given-names>SC</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><name><surname>Huang</surname><given-names>SH</given-names></name><name><surname>Erdos</surname><given-names>G</given-names></name><name><surname>Kenniston</surname><given-names>TW</given-names></name><name><surname>Carey</surname><given-names>CD</given-names></name><name><surname>Joachim</surname><given-names>SM</given-names></name><name><surname>Conter</surname><given-names>LJ</given-names></name><name><surname>Weisel</surname><given-names>NM</given-names></name><name><surname>Okba</surname><given-names>NMA</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Percivalle</surname><given-names>E</given-names></name><name><surname>Cassaniti</surname><given-names>I</given-names></name><name><surname>Baldanti</surname><given-names>F</given-names></name><name><surname>Korkmaz</surname><given-names>E</given-names></name><name><surname>Shlomchik</surname><given-names>MJ</given-names></name><name><surname>Falo</surname><given-names>LD</given-names></name><name><surname>Gambotto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice</article-title><source>European Journal of Immunology</source><volume>51</volume><fpage>1774</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1002/eji.202149167</pub-id><pub-id pub-id-type="pmid">33772778</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>JS</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Few and far between: how HIV may be evading antibody avidity</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1000908</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000908</pub-id><pub-id pub-id-type="pmid">20523901</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosawa</surname><given-names>N</given-names></name><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Isobe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Target-selective homologous recombination cloning for high-throughput generation of monoclonal antibodies from single plasma cells</article-title><source>BMC Biotechnology</source><volume>11</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-11-39</pub-id><pub-id pub-id-type="pmid">21486488</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosawa</surname><given-names>N</given-names></name><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>R</given-names></name><name><surname>Yamagishi</surname><given-names>F</given-names></name><name><surname>Isobe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rapid production of antigen-specific monoclonal antibodies from a variety of animals</article-title><source>BMC Biology</source><volume>10</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-10-80</pub-id><pub-id pub-id-type="pmid">23017270</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapuente</surname><given-names>D</given-names></name><name><surname>Fuchs</surname><given-names>J</given-names></name><name><surname>Willar</surname><given-names>J</given-names></name><name><surname>Vieira AntÃ£o</surname><given-names>A</given-names></name><name><surname>Eberlein</surname><given-names>V</given-names></name><name><surname>Uhlig</surname><given-names>N</given-names></name><name><surname>Issmail</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Oltmanns</surname><given-names>F</given-names></name><name><surname>Peter</surname><given-names>AS</given-names></name><name><surname>Mueller-Schmucker</surname><given-names>S</given-names></name><name><surname>Irrgang</surname><given-names>P</given-names></name><name><surname>Fraedrich</surname><given-names>K</given-names></name><name><surname>Cara</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>PÃ¶hlmann</surname><given-names>S</given-names></name><name><surname>Ensser</surname><given-names>A</given-names></name><name><surname>Pertl</surname><given-names>C</given-names></name><name><surname>Willert</surname><given-names>T</given-names></name><name><surname>Thirion</surname><given-names>C</given-names></name><name><surname>Grunwald</surname><given-names>T</given-names></name><name><surname>Ãberla</surname><given-names>K</given-names></name><name><surname>Tenbusch</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>6871</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-27063-4</pub-id><pub-id pub-id-type="pmid">34836955</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The effects of secretory IgA in the mucosal immune system</article-title><source>BioMed Research International</source><volume>2020</volume><elocation-id>2032057</elocation-id><pub-id pub-id-type="doi">10.1155/2020/2032057</pub-id><pub-id pub-id-type="pmid">31998782</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltseva</surname><given-names>M</given-names></name><name><surname>Galipeau</surname><given-names>Y</given-names></name><name><surname>Renner</surname><given-names>TM</given-names></name><name><surname>Deschatelets</surname><given-names>L</given-names></name><name><surname>Durocher</surname><given-names>Y</given-names></name><name><surname>Akache</surname><given-names>B</given-names></name><name><surname>Langlois</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Characterization of systemic and mucosal humoral immune responses to an adjuvanted intranasal SARS-CoV-2 protein subunit vaccine candidate in mice</article-title><source>Vaccines</source><volume>11</volume><elocation-id>MC9865305</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11010030</pub-id><pub-id pub-id-type="pmid">36679875</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcotte</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>F</given-names></name><name><surname>Simonelli</surname><given-names>L</given-names></name><name><surname>Sammartino</surname><given-names>JC</given-names></name><name><surname>Pedotti</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Cassaniti</surname><given-names>I</given-names></name><name><surname>Hagbom</surname><given-names>M</given-names></name><name><surname>Piralla</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Percivalle</surname><given-names>E</given-names></name><name><surname>Bertoglio</surname><given-names>F</given-names></name><name><surname>Schubert</surname><given-names>M</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Sherina</surname><given-names>N</given-names></name><name><surname>Guerra</surname><given-names>C</given-names></name><name><surname>Borte</surname><given-names>S</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name><name><surname>Kumagai-Braesch</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>GrÃ¶nwall</surname><given-names>C</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Calzolai</surname><given-names>L</given-names></name><name><surname>Cavalli</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Hust</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Svensson</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Baldanti</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>HammarstrÃ¶m</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Varani</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name><name><surname>Pan-HammarstrÃ¶m</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages</article-title><source>PNAS</source><volume>121</volume><elocation-id>e2315354120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2315354120</pub-id><pub-id pub-id-type="pmid">38194459</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Molecular mechanisms of multimeric assembly of IgM and IgA</article-title><source>Annual Review of Immunology</source><volume>40</volume><fpage>221</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101320-123742</pub-id><pub-id pub-id-type="pmid">35061510</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Maruyama</surname><given-names>J</given-names></name><name><surname>Nao</surname><given-names>N</given-names></name><name><surname>Manzoor</surname><given-names>R</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e85582</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085582</pub-id><pub-id pub-id-type="pmid">24465606</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsuka</surname><given-names>J</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Fukumura</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Eguchi</surname><given-names>A</given-names></name><name><surname>Ono</surname><given-names>R</given-names></name><name><surname>Maemura</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Yamayoshi</surname><given-names>S</given-names></name><name><surname>Kataoka</surname><given-names>Y</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Nosaka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2</article-title><source>iScience</source><volume>24</volume><elocation-id>103379</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.103379</pub-id><pub-id pub-id-type="pmid">34805782</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuya</surname><given-names>K</given-names></name><name><surname>Eguchi</surname><given-names>N</given-names></name><name><surname>Manzoor</surname><given-names>R</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kida</surname><given-names>Y</given-names></name><name><surname>Mori-Kajihara</surname><given-names>A</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Ichii</surname><given-names>O</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Higashi</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Comparative analyses of the antiviral activities of IgG and IgA antibodies to influenza a virus M2 protein</article-title><source>Viruses</source><volume>12</volume><elocation-id>780</elocation-id><pub-id pub-id-type="doi">10.3390/v12070780</pub-id><pub-id pub-id-type="pmid">32698456</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuya</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Manzoor</surname><given-names>R</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kida</surname><given-names>Y</given-names></name><name><surname>Mori-Kajihara</surname><given-names>A</given-names></name><name><surname>Kondoh</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Ichii</surname><given-names>O</given-names></name><name><surname>Higashi</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Potential role of nonneutralizing iga antibodies in cross-protective immunity against influenza a viruses of multiple hemagglutinin subtypes</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>e00408-20</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00408-20</pub-id><pub-id pub-id-type="pmid">32269119</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Tani</surname><given-names>H</given-names></name><name><surname>Anraku</surname><given-names>Y</given-names></name><name><surname>Kita</surname><given-names>S</given-names></name><name><surname>Igarashi</surname><given-names>E</given-names></name><name><surname>Saga</surname><given-names>Y</given-names></name><name><surname>Inasaki</surname><given-names>N</given-names></name><name><surname>Kawasuji</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>SI</given-names></name><name><surname>Somekawa</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>J</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Morinaga</surname><given-names>Y</given-names></name><name><surname>Kurosawa</surname><given-names>N</given-names></name><name><surname>Isobe</surname><given-names>M</given-names></name><name><surname>Fukuhara</surname><given-names>H</given-names></name><name><surname>Maenaka</surname><given-names>K</given-names></name><name><surname>Hashiguchi</surname><given-names>T</given-names></name><name><surname>Kishi</surname><given-names>H</given-names></name><name><surname>Kitajima</surname><given-names>I</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Niimi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants</article-title><source>mAbs</source><volume>14</volume><elocation-id>2072455</elocation-id><pub-id pub-id-type="doi">10.1080/19420862.2022.2072455</pub-id><pub-id pub-id-type="pmid">35543180</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>JL</given-names></name><name><surname>PÃ©rez Marc</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>ED</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Swanson</surname><given-names>KA</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Kalina</surname><given-names>WV</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name><surname>Hammitt</surname><given-names>LL</given-names></name><name><surname>TÃ¼reci</surname><given-names>Ã</given-names></name><name><surname>Nell</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Ãnal</surname><given-names>S</given-names></name><name><surname>Tresnan</surname><given-names>DB</given-names></name><name><surname>Mather</surname><given-names>S</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Åahin</surname><given-names>U</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Gruber</surname><given-names>WC</given-names></name><collab>C4591001 Clinical Trial Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Ainai</surname><given-names>A</given-names></name><name><surname>Taga</surname><given-names>Y</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Tabata</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Ohara</surname><given-names>Y</given-names></name><name><surname>Takeyama</surname><given-names>H</given-names></name><name><surname>Odagiri</surname><given-names>T</given-names></name><name><surname>Kageyama</surname><given-names>T</given-names></name><name><surname>Ogawa-Goto</surname><given-names>K</given-names></name><name><surname>Multihartina</surname><given-names>P</given-names></name><name><surname>Setiawaty</surname><given-names>V</given-names></name><name><surname>Pangesti</surname><given-names>KNA</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1007427</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007427</pub-id><pub-id pub-id-type="pmid">30605488</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikh-Mohamed</surname><given-names>S</given-names></name><name><surname>Isho</surname><given-names>B</given-names></name><name><surname>Chao</surname><given-names>GYC</given-names></name><name><surname>Zuo</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Lustig</surname><given-names>Y</given-names></name><name><surname>Nahass</surname><given-names>GR</given-names></name><name><surname>Salomon-Shulman</surname><given-names>RE</given-names></name><name><surname>Blacker</surname><given-names>G</given-names></name><name><surname>Fazel-Zarandi</surname><given-names>M</given-names></name><name><surname>Rathod</surname><given-names>B</given-names></name><name><surname>Colwill</surname><given-names>K</given-names></name><name><surname>Jamal</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>de Launay</surname><given-names>KQ</given-names></name><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Garnham-Takaoka</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Fahim</surname><given-names>C</given-names></name><name><surname>Paterson</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>AX</given-names></name><name><surname>Haq</surname><given-names>N</given-names></name><name><surname>Barati</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Mozafarihashjin</surname><given-names>M</given-names></name><name><surname>Samaan</surname><given-names>P</given-names></name><name><surname>Budylowski</surname><given-names>P</given-names></name><name><surname>Siqueira</surname><given-names>WL</given-names></name><name><surname>Mubareka</surname><given-names>S</given-names></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Rini</surname><given-names>JM</given-names></name><name><surname>Rojas</surname><given-names>OL</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Tal</surname><given-names>MC</given-names></name><name><surname>McGeer</surname><given-names>A</given-names></name><name><surname>Regev-Yochay</surname><given-names>G</given-names></name><name><surname>Straus</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>A-C</given-names></name><name><surname>Gommerman</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection</article-title><source>Mucosal Immunology</source><volume>15</volume><fpage>799</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/s41385-022-00511-0</pub-id><pub-id pub-id-type="pmid">35468942</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimoda</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Asanuma</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>S</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Mizuochi</surname><given-names>T</given-names></name><name><surname>Azuma</surname><given-names>N</given-names></name><name><surname>Kanno</surname><given-names>C</given-names></name><name><surname>Takemori</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue</article-title><source>The Journal of Experimental Medicine</source><volume>194</volume><fpage>1597</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1084/jem.194.11.1597</pub-id><pub-id pub-id-type="pmid">11733574</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterlin</surname><given-names>D</given-names></name><name><surname>Malaussena</surname><given-names>A</given-names></name><name><surname>Gorochov</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>IgA dominates the early neutralizing antibody response to SARS-CoV-2 virus</article-title><source>M S-Medecine Sciences</source><volume>37</volume><fpage>968</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1051/medsci/2021154</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Prabhu</surname><given-names>SK</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Venzon</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Teow</surname><given-names>E</given-names></name><name><surname>Velasco</surname><given-names>J</given-names></name><name><surname>Greenhouse</surname><given-names>J</given-names></name><name><surname>Putman-Taylor</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>TA</given-names></name><name><surname>Pessaint</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>IN</given-names></name><name><surname>Lagenaur</surname><given-names>L</given-names></name><name><surname>Talton</surname><given-names>J</given-names></name><name><surname>Breed</surname><given-names>MW</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Bock</surname><given-names>KW</given-names></name><name><surname>Minai</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>BM</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Wang</surname><given-names>LX</given-names></name><name><surname>Berzofsky</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>MC8262352</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.148494</pub-id><pub-id pub-id-type="pmid">33908897</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungnak</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>BÃ©cavin</surname><given-names>C</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Queen</surname><given-names>R</given-names></name><name><surname>Litvinukova</surname><given-names>M</given-names></name><name><surname>Talavera-LÃ³pez</surname><given-names>C</given-names></name><name><surname>Maatz</surname><given-names>H</given-names></name><name><surname>Reichart</surname><given-names>D</given-names></name><name><surname>Sampaziotis</surname><given-names>F</given-names></name><name><surname>Worlock</surname><given-names>KB</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>JL</given-names></name><collab>HCA Lung Biological Network</collab></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nature Medicine</source><volume>26</volume><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0868-6</pub-id><pub-id pub-id-type="pmid">32327758</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tudor</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Maupetit</surname><given-names>J</given-names></name><name><surname>Drillet</surname><given-names>AS</given-names></name><name><surname>Bouceba</surname><given-names>T</given-names></name><name><surname>Schwartz-Cornil</surname><given-names>I</given-names></name><name><surname>Lopalco</surname><given-names>L</given-names></name><name><surname>Tuffery</surname><given-names>P</given-names></name><name><surname>Bomsel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody</article-title><source>PNAS</source><volume>109</volume><fpage>12680</fpage><lpage>12685</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200024109</pub-id><pub-id pub-id-type="pmid">22723360</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumpey</surname><given-names>TM</given-names></name><name><surname>Renshaw</surname><given-names>M</given-names></name><name><surname>Clements</surname><given-names>JD</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection</article-title><source>Journal of Virology</source><volume>75</volume><fpage>5141</fpage><lpage>5150</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.11.5141-5150.2001</pub-id><pub-id pub-id-type="pmid">11333895</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vabret</surname><given-names>N</given-names></name><name><surname>Britton</surname><given-names>GJ</given-names></name><name><surname>Gruber</surname><given-names>C</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kuksin</surname><given-names>M</given-names></name><name><surname>Levantovsky</surname><given-names>R</given-names></name><name><surname>Malle</surname><given-names>L</given-names></name><name><surname>Moreira</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>MD</given-names></name><name><surname>Pia</surname><given-names>L</given-names></name><name><surname>Risson</surname><given-names>E</given-names></name><name><surname>Saffern</surname><given-names>M</given-names></name><name><surname>SalomÃ©</surname><given-names>B</given-names></name><name><surname>Esai Selvan</surname><given-names>M</given-names></name><name><surname>Spindler</surname><given-names>MP</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>van der Heide</surname><given-names>V</given-names></name><name><surname>Gregory</surname><given-names>JK</given-names></name><name><surname>Alexandropoulos</surname><given-names>K</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>BD</given-names></name><name><surname>Greenbaum</surname><given-names>B</given-names></name><name><surname>GÃ¼mÃ¼Å</surname><given-names>ZH</given-names></name><name><surname>Homann</surname><given-names>D</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Curotto de Lafaille</surname><given-names>MA</given-names></name><name><surname>Mehandru</surname><given-names>S</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Samstein</surname><given-names>RM</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Aleynick</surname><given-names>M</given-names></name><name><surname>Belabed</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Casanova-Acebes</surname><given-names>M</given-names></name><name><surname>Catalan</surname><given-names>J</given-names></name><name><surname>Centa</surname><given-names>M</given-names></name><name><surname>Charap</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>ST</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Bozkus</surname><given-names>CC</given-names></name><name><surname>Cody</surname><given-names>E</given-names></name><name><surname>Cossarini</surname><given-names>F</given-names></name><name><surname>Dalla</surname><given-names>E</given-names></name><name><surname>Fernandez</surname><given-names>N</given-names></name><name><surname>Grout</surname><given-names>J</given-names></name><name><surname>Ruan</surname><given-names>DF</given-names></name><name><surname>Hamon</surname><given-names>P</given-names></name><name><surname>Humblin</surname><given-names>E</given-names></name><name><surname>Jha</surname><given-names>D</given-names></name><name><surname>Kodysh</surname><given-names>J</given-names></name><name><surname>Leader</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Lindblad</surname><given-names>K</given-names></name><name><surname>Lozano-Ojalvo</surname><given-names>D</given-names></name><name><surname>Lubitz</surname><given-names>G</given-names></name><name><surname>Magen</surname><given-names>A</given-names></name><name><surname>Mahmood</surname><given-names>Z</given-names></name><name><surname>Martinez-Delgado</surname><given-names>G</given-names></name><name><surname>Mateus-Tique</surname><given-names>J</given-names></name><name><surname>Meritt</surname><given-names>E</given-names></name><name><surname>Moon</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>J</given-names></name><name><surname>OâDonnell</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Plitt</surname><given-names>T</given-names></name><name><surname>Pothula</surname><given-names>V</given-names></name><name><surname>Redes</surname><given-names>J</given-names></name><name><surname>Reyes Torres</surname><given-names>I</given-names></name><name><surname>Roberto</surname><given-names>M</given-names></name><name><surname>Sanchez-Paulete</surname><given-names>AR</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Schanoski</surname><given-names>AS</given-names></name><name><surname>Suprun</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>M</given-names></name><name><surname>Vaninov</surname><given-names>N</given-names></name><name><surname>Wilk</surname><given-names>CM</given-names></name><name><surname>Aguirre-Ghiso</surname><given-names>J</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Faith</surname><given-names>J</given-names></name><name><surname>Grasset</surname><given-names>E</given-names></name><name><surname>Heeger</surname><given-names>P</given-names></name><name><surname>Kenigsberg</surname><given-names>E</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Laserson</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunology of COVID-19: current state of the science</article-title><source>Immunity</source><volume>52</volume><fpage>910</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.002</pub-id><pub-id pub-id-type="pmid">32505227</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Viant</surname><given-names>C</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Oren</surname><given-names>DA</given-names></name><name><surname>Ramos</surname><given-names>V</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Enhanced SARS-CoV-2 neutralization by dimeric IgA</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>MC7857415</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abf1555</pub-id><pub-id pub-id-type="pmid">33288661</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Russ</surname><given-names>BP</given-names></name><name><surname>Horspool</surname><given-names>AM</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Winters</surname><given-names>MT</given-names></name><name><surname>Allison Wolf</surname><given-names>M</given-names></name><name><surname>Rader</surname><given-names>NA</given-names></name><name><surname>Miller</surname><given-names>OA</given-names></name><name><surname>Shiflett</surname><given-names>M</given-names></name><name><surname>Izac</surname><given-names>J</given-names></name><name><surname>Varisco</surname><given-names>D</given-names></name><name><surname>Sen-Kilic</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Cyphert</surname><given-names>HA</given-names></name><name><surname>Barbier</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>I</given-names></name><name><surname>Bevere</surname><given-names>JR</given-names></name><name><surname>Ernst</surname><given-names>RK</given-names></name><name><surname>Damron</surname><given-names>FH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge</article-title><source>NPJ Vaccines</source><volume>7</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1038/s41541-022-00451-7</pub-id><pub-id pub-id-type="pmid">35288576</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woof</surname><given-names>JM</given-names></name><name><surname>Kerr</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The function of immunoglobulin A in immunity</article-title><source>The Journal of Pathology</source><volume>208</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/path.1877</pub-id><pub-id pub-id-type="pmid">16362985</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Kurosawa</surname><given-names>N</given-names></name><name><surname>Isobe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Target-selective joint polymerase chain reaction: a robust and rapid method for high-throughput production of recombinant monoclonal antibodies from single cells</article-title><source>BMC Biotechnology</source><volume>11</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-11-75</pub-id><pub-id pub-id-type="pmid">21774833</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>JFW</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Robinot</surname><given-names>R</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Kwong</surname><given-names>HYH</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>CCS</given-names></name><name><surname>Poon</surname><given-names>VKM</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Yue</surname><given-names>M</given-names></name><name><surname>Kwan</surname><given-names>KY</given-names></name><name><surname>Chan</surname><given-names>CY</given-names></name><name><surname>Chan</surname><given-names>CCY</given-names></name><name><surname>Chik</surname><given-names>KKH</given-names></name><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Au</surname><given-names>KK</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Man</surname><given-names>HO</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Yeung</surname><given-names>ML</given-names></name><name><surname>To</surname><given-names>KKW</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Chakrabarti</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters<sup>1</sup></article-title><source>Emerging Microbes &amp; Infections</source><volume>12</volume><elocation-id>2245921</elocation-id><pub-id pub-id-type="doi">10.1080/22221751.2023.2245921</pub-id><pub-id pub-id-type="pmid">37542391</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhuang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Jaen</surname><given-names>AM</given-names></name><name><surname>Do</surname><given-names>TH</given-names></name><name><surname>Peter</surname><given-names>JG</given-names></name><name><surname>Dorado</surname><given-names>AG</given-names></name><name><surname>Tirador</surname><given-names>LS</given-names></name><name><surname>Zabat</surname><given-names>GMA</given-names></name><name><surname>Villalobos</surname><given-names>REM</given-names></name><name><surname>Gueco</surname><given-names>GP</given-names></name><name><surname>Botha</surname><given-names>LLG</given-names></name><name><surname>Iglesias Pertuz</surname><given-names>SP</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Quan</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Team</surname><given-names>CPS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>The Lancet. Respiratory Medicine</source><volume>11</volume><fpage>1075</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(23)00349-1</pub-id><pub-id pub-id-type="pmid">37979588</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88387.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This work provides <bold>important</bold> insights into mucosal antibody responses against SARS-CoV-2 following intranasal immunization by characterizing a large number of monoclonal antibodies at both mucosal and non-mucosal sites. The evidence supporting the claims is <bold>solid</bold>. The demonstrated in vitro antiviral activity of antibodies characterized provides a rationale for developing mucosal vaccines, especially if confirmed in vivo and benchmarked against antibodies generated following intramuscular vaccination.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88387.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Demonstrate the breadth of IgA response as determined by isolating individual antigen-specific B cells and generating mAbs in mice following intranasal immunization of mice with SARS-CoV2 Spike protein. The findings show that some IgA mAb can neutralize the virus, but many do not. Notable immunization with Wuhan S protein generates a weak response to the omicron variant.</p><p>Strengths:</p><p>Detailed analysis characterizing individual B cells with the generation of mAbs demonstrates the response's breadth and diversity of IgA responses and the ability to generate systemic immune responses.</p><p>Comments on Revision:</p><p>I have re-reviewed the paper and responses to my and other reviewers' comments. I feel the authors have adequately addressed my and other reviewer's comments.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88387.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waki</surname><given-names>Kentarou</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Tani</surname><given-names>Hideki</given-names></name><role specific-use="author">Author</role><aff><institution>Toyama Institute of Health</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>Eigo</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Saga</surname><given-names>Yumiko</given-names></name><role specific-use="author">Author</role><aff><institution>Toyama Institute of Health</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Takahisa</given-names></name><role specific-use="author">Author</role><aff><institution>Toyama Institute of Health</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Yamazaki</surname><given-names>Emiko</given-names></name><role specific-use="author">Author</role><aff><institution>Toyama Institute of Health</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Koike</surname><given-names>Seiichi</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Morinaga</surname><given-names>Yoshitomo</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Isobe</surname><given-names>Masaharu</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kurosawa</surname><given-names>Nobuyuki</given-names></name><role specific-use="author">Author</role><aff><institution>University of Toyama</institution><addr-line><named-content content-type="city">Toyama</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Despite evidence suggesting the benefits of neutralizing mucosa-derived IgA in the upper airway in protection against the SARS-CoV-2 virus, all currently approved vaccines are administered intramuscularly, which mainly induces systemic IgG. Waki et al. aimed to characterize the benefits of intranasal vaccination at the molecular level by isolating B cell clones from nasal tissue. The authors found that Spike-specific plasma cells isolated from the spleen of vaccinated mice showed significant clonal overlap with Spikespecific plasma cells isolated from nasal tissue. Interestingly, they could not detect any spike-specific plasma cells in the bone marrow or Peyer's patches, indicating that these nose-derived cells did not necessarily home to and reside in these locations, although the Peyer's patch is not a typical plasma cell niche - rather the lamina propria of the gut would have been a better place to look. Furthermore, they found that multimerization improves the antibody/antigen binding when the antibody is of low or intermediate affinity, but that high-affinity monomeric antibodies do not benefit from multimerization. Lastly, the authors used a competitive ELISA assay to show that multimerization could improve the neutralizing capacity of these</p><p>antibodies.</p><p>The strength of this paper is the cloning of multiple IgA from the nasal mucosae (n=99) and the periphery (n=114) post-SARS-CoV-2 i.n. vaccination to examine the clonal relationship of this IgA with other sites, including the spleen. This analysis provides novel insights into the nature of the mucosal antibody response at the site where the host would encounter the virus, and whether this IgA response disseminates to other</p><p>tissues.</p><p>There were also some weaknesses:</p><p>(1) The finding that multimerization improves binding and neutralization is not surprising as this was observed before by Wang and Nussenzweig for anti-SARS-CoV-2 IgA (authors should cite Enhanced SARS-CoV-2 neutralization by dimeric IgA. Wang et al., Sci. Transl. Med 2021, 13:3abf1555).</p></disp-quote><p>We have cited the paper, and the relevant sentence has been modified as follows (line 51-53); Recent studies have demonstrated that multimeric IgA is more effective and provides greater cross-protection than IgG and M-IgA (Okuya et al., 2020b) (Asahi et al., 2002) (Dhakal et al., 2018) (Asahi-Ozaki et al., 2004) (Wang et al., 2021).</p><disp-quote content-type="editor-comment"><p>In addition, as far as I can tell we cannot ascertain the purity of fractions from the size exclusion chromatography thus I wasn't sure whether the input material used in Fig. 4 was a mixed population of dimer/trimer/tetramer?</p></disp-quote><p>The S-IgAs used in the SPR analysis in Fig. 4 consist of a mixture of dimers, trimers, and tetramers. The observed values indicate the average affinity of the S-IgAs. Please refer to the revised version (line 278280).</p><disp-quote content-type="editor-comment"><p>(2) The flow cytometric assessment of the IgA+ clones from the nasal mucosae was difficult to interpret (Fig. 1B). It was hard for me to tell what they were gating on and subsequently analyzing without an IgA-negative population for reference.</p></disp-quote><p>We have updated FACS plots to illustrate the presence of IgA+ plasma cells in Fig. 1B, and the detailed gating strategy is outlined in Fig. 1B legend. Please find the relevant statements (line 115-120).</p><disp-quote content-type="editor-comment"><p>(3) While the i.n. study itself is large and challenging, it would have been interesting to compare an i.m. route and examine the breadth of SARS-CoV-2 variant S1 binding for IgGs as in Fig. 2A. Are the IgA responses derived from the mucosae of greater breadth than systemic IgG responses? Alternatively, and easier, authors could do some comparisons with well-characterized IgG mAb for affinity and cross-reactivity as a benchmark to compare with the IgAs they looked at. Overall the authors did a good job of looking at a large range of systemic vs mucosal S1-specific antibodies in the context of an intra-nasal vaccination and this provides additional evidence for the utility of mucosal vaccination approaches for reducing person-to-person transmission.</p></disp-quote><p>I appreciate your consideration. Recent reports indicate that some M-IgA monomers possess neutralizing activity that is equivalent to or less than that of IgGs. However, the opposite phenomenon has also been observed. These results suggest that the Fc does not merely correlate with the degree of increase in antibody reactivity or functionality. We believe the discrepancies in previous studies are due to variations in the binding modes between the epitope and paratope of each antibody clone. Nevertheless, oligomerization enhances the functionality of most monomeric antibody clones, suggesting that the multivalent S-IgA enables a mode of action that is challenging to achieve with a monomeric antibody. Please refer to the revised version (line 399-403).</p><disp-quote content-type="editor-comment"><p>Alternatively, and easier, authors could do some comparisons with well-characterized IgG mAb for affinity and cross-reactivity as a benchmark to compare with the IgAs they looked at. Overall the authors did a good job of looking at a large range of systemic vs mucosal S1-specific antibodies in the context of an intra-nasal vaccination and this provides additional evidence for the utility of mucosal vaccination approaches for reducing person-to-person transmission.</p></disp-quote><p>We have summarized the characteristics of the four types of nasal IgAs in Fig.7 and in the Discussion. Please refer to the revised version (line 405-422).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This research demonstrates the breadth of IgA response as determined by isolating individual antigenspecific B cells and generating mAbs in mice following intranasal immunization of mice with SARS-CoV2 Spike protein. The findings show that some IgA mAb can neutralize the virus, but many do not. Notable immunization with Wuhan S protein generates a weak response to the omicron variant.</p><p>Strengths:</p><p>Detailed analysis characterizing individual B cells with the generation of mAbs demonstrates the response's breadth and diversity of IgA responses and the ability to generate systemic immune responses.</p><p>Weaknesses:</p><p>The data presentation needs clarity, and results show mAb ability to inhibit SARS-CoV2 in vitro. How IgA functions in vivo is uncertain.</p></disp-quote><p>We conducted an additional experiment using a hamster model and confirmed that S-IgAs can protect against SARS-CoV-2 infection. Please refer to the revised version (line 349-373 and 431-438).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) Figure 1A shows antibody titers in nasal lavage fluid and serum of mice post intranasal vaccination with SARS-CoV-2 Spike protein. The Y-axis of this figure is labeled as &quot;U/mg&quot; however these units are not clearly defined.</p></disp-quote><p>The antibody titers are expressed as optical density (OD450) value per total protein in nasal lavage fluids or serum. Please find the relevant statements (line 113-114).</p><disp-quote content-type="editor-comment"><p>Furthermore, what do antibody titers in the nasal lavage fluid and serum look like post-intramuscular vaccination with the same vaccine and dose? Comparison of titers to the intramuscular route as well as to the PBS control would make this data more impactful.</p></disp-quote><p>We appreciate your consideration. We have not conducted experiments comparing the effects of intramuscular and intranasal administration using the same dosage and adjuvant. Cholera toxin has primarily been used as an adjuvant for nasal immunization, but it is seldom applied for intramuscular injection. We are interested in its impact on the immune compartment when using cholera toxin as an adjuvant for intramuscular injection. We plan to conduct further experiments in the future.</p><disp-quote content-type="editor-comment"><p>Lastly, in Figure 1B, the detection of nasal IgG is not shown even though the authors assess nasally-derived IgG in the spleen further into the study.</p></disp-quote><p>Since the number of lymphocytes that can be collected from the nasal mucosa is limited, there is an insufficient capacity to isolate IgG+ plasma cells after collecting IgA+ plasma cells. Therefore, conducting such an experiment on mice is technically challenging. A larger animal, such as rats, will be necessary to perform this experiment. Further investigation is needed to determine whether antigen-specific IgG+ plasma cells, sharing V-(D)-J with nasal IgA, can be detected in the nasal mucosa.</p><disp-quote content-type="editor-comment"><p>(2) There appears to be something amiss with the IgA stain. It is smushed up against the X-axis. Better flow cytometry profiles should be shown. Likewise in Supplemental Fig. 1A, their IgA stain appears to not be working. This must be addressed using positive and negative controls.</p></disp-quote><p>We have updated FACS-polts to show the IgA+ plasma cell in Fig.1B, and the detailed gating strategy is outlined in the Fig.1B legend. Please find the relevant statements on line 115-120.</p><disp-quote content-type="editor-comment"><p>(3) We do not know the purity of the samples that were subjected to SPR and since the legend of Fig. 4 is partially incorrect, it was difficult to know how this experiment was done.</p></disp-quote><p>The S-IgA used in the SPR analysis shown in Figure 4 is a mixture of dimers, trimers, and tetramers, and the observed values are believed to reflect the affinity of the S-IgA in the nasal mucosa. Please refer to the revised version (line 278-280).</p><disp-quote content-type="editor-comment"><p>(4) Fig. 5 results need to compare with some of the well-characterized mAb (IgG) to understand the biological significance of these neutralizing titres.</p></disp-quote><p>We have summarized the characteristics of the four types of nasal IgA in Fig.7 and in the Discussion. Please refer to the revised version (page 405-422).</p><disp-quote content-type="editor-comment"><p>Communication of results:</p><p>(1) Authors could improve the communication of their results by introducing the vaccination protocol in the results section accompanied by a diagram of the vaccination strategy (nature of the Ag, route, and frequency). This could be Fig. 1A .</p></disp-quote><p>A schematic diagram of the vaccination protocol is presented in Fig.1.</p><disp-quote content-type="editor-comment"><p>(2) Care should be taken with some of the terminology. Intranasal is the accepted term but authors sometimes use &quot;internasal&quot;. The term &quot;immunosuppression&quot; on page 2 could be misleading as it means something different to other audiences. The distinction when speaking about &quot;protection from harmful pathogens&quot; should be made between protection against infection (ie sterilizing immunity) vs protection against disease (ie morbidity and mortality). Instead of &quot;nose&quot;, one should say &quot;nasal&quot;. Nose-related could be rephrased as &quot;potentially nasal-derived&quot;. P.5, line 2 didn't make sense: &quot;IgG+ plasma cells that express nose-related IgA&quot;...</p><p>In many places, Spike is missing it's &quot;e&quot;.</p></disp-quote><p>We have made the correction accordingly.</p><disp-quote content-type="editor-comment"><p>(3) Page 3: The lumping of the human and animal SARS-CoV-2 intranasal studies together is a bit misleading. Very little has worked for intranasal vaccination against SARS-CoV-2 in humans at this point in time (although hopefully that will change soon!). Authors should specify which studies were done in animals and which were done in humans.</p></disp-quote><p>The manuscript has been revised to include two citations on line 73-75 (Ewer et al., 2021 and Zhu et al., 2023).</p><disp-quote content-type="editor-comment"><p>(4) What is ER-tracker? It comes out of nowhere and should be explained why it was used to the reader (as well as why they used the other markers) to sort for Spike-specific PC.</p></disp-quote><p>ER-Tracker is a fluorescent dye that is highly selective for the endoplasmic reticulum of living cells. Because plasma cells have an expanded endoplasmic reticulum for properly folding and secreting large quantities of antibodies, using ER-Tracker along with anti-CD138 facilitates the isolation of plasma cells from lymphocytes without the need for additional antibodies. Please refer to the revised version for details. (ine 130-134).</p></body></sub-article></article>